

## CURRICULUM VITAE

Bruce William Stanley ROBINSON

### 1. PERSONAL DETAILS

DATE OF BIRTH: 2 June 1950  
PLACE OF BIRTH: Perth, Western Australia  
NATIONALITY: Australian  
CIVIL STATUS: Married: Jacqueline Spencer (nee Pocock)  
Children: Simon Andrew                      DOB: 16.8.81  
              Scott Benjamin                 DOB: 27.9.84  
              Amy Jean                         DOB: 29.3.88

#### ADDRESSES:

Work:                      School of Medicine  
                              University of Western Australia, M503  
                              35 Stirling Hwy CRAWLEY WA 6009 AUSTRALIA  
                              Tel: (08) 6151 0915 Fax: (08) 6151 1027 (national)  
                              Tel: 61 8 6151 0915 Fax: 61 8 6151 1027 (international)  
Home:                     33 Evans Street  
                              SHENTON PARK WA 6008 AUSTRALIA  
                              Tel: (08) 9381 5053

### 2. EDUCATION; AWARDS; SCHOLARSHIPS AND FELLOWSHIPS

#### 2.1 Educational Qualifications

Matriculation	1967	Perth, Western Australia (5 distinctions)
MBBS	1974	University of Western Australia
DTM&H	1976	University of Liverpool (School of Tropical Medicine)
MRCP	1977	Royal College of Physicians (United Kingdom)
FRACP	1981	Royal Australasian College of Physicians
FCCP	1987	American College of Chest Physicians
MD	1987	University of Western Australia
FRCP	1995	Royal College of Physicians (UK)

#### 2.2 Awards

Royal Australasian College of Physicians (RACP) 75<sup>th</sup> Anniversary Award, 2014.

WA Australian of the Year, 2014.

Western Australian of the Year 2013.

Winner, Business and Professions Category, Western Australian of the Year Awards, 2013.

Member of the Order of Australia (General Division), Australia Day Honours List, 2013, for significant service to medicine in the area of research into asbestos-related cancers, and to the community, particularly through support to fathers.

The Ernst & Young Entrepreneur of the Year Award, 2011, for the International Skills and Training Institute in Health (ISTIH).

The Australian Medical Association Award, 2010, for outstanding contributions to a variety of fields of medicine.

The Research Medal of the Thoracic Society of Australia and New Zealand, March 2007. This Award is made in recognition of outstanding contributions to scientific research.

The Premier's Science Award, Western Australia, 2004. Presented to the individual chosen by the Premier's Science Council for their achievements and leadership in science.

The Wagner Medal, 2004. An award made every second year by the committee of the International Mesothelioma Interest Group and presented at their International Conference to the individual who is judged to have made the leading contribution to mesothelioma research over a number of years.

The Gordon Ada Oration, Australasian Society for Immunology, Tumour Immunology Workshop, December 2004.

The Teacher of the Year award, 1999, The University of Western Australia, School of Medicine (selected by the medical student body).

The Excellence in Teaching award, 1997, The University of Western Australia, Faculty of Medicine & Dentistry.

The Eric G Saint Award, 1996, for contributions to research into asbestos-related diseases.

The Teacher of the Year award, 1990, The University of Western Australia, School of Medicine (selected by the medical student body).

The Young Investigator Award of the Thoracic Society of Australia, 1986, for 'The most outstanding scientific work by an investigator under 36 years of age'.

#### Scholarships/Fellowships awarded:

NH & MRC Special Training Fellowship 1986

NH & MRC Applied Health Sciences Fellowship 1983-1985

Royal Australasian College of Physicians Overseas Fellowship 1982

Saw Medical Research Fellowship 1982

Commonwealth University Scholarship 1968-1973

Commonwealth Secondary Scholarship 1964-1967

### **3. EXPERIENCE**

1995-present	<i>Professor of Medicine Department of Medicine, The University of Western Australia Sir Charles Gairdner Hospital, Perth, Western Australia.</i>
1984-present	<i>Consultant Physician Department of Respiratory Medicine (plus General Medicine 1988-1997) Sir Charles Gairdner Hospital, Perth, Western Australia.</i>
2007-present	<i>Director, National Research Centre for Asbestos Related Diseases (NCARD) The University of Western Australia, Perth Western, Australia</i>
1997-1999	<i>Director, Institute for Advanced Medical Research The University of Western Australia</i>
1996-2001	<i>Director, Office of Research Development Sir Charles Gairdner Hospital, Perth, Western Australia.</i>
1992	<i>Sabbatical Leave c/-Professor J Lamb Department of Immunology, St Mary's Hospital Medical School London, United Kingdom.</i>
1991-1994	<i>Associate Professor of Medicine Department of Medicine, The University of Western Australia Sir Charles Gairdner Hospital, Perth, Western Australia</i>
1988-1990	<i>Senior Lecturer in Medicine Department of Medicine, The University of Western Australia</i>
1984-1987	<i>Research Fellow Department of Medicine, The University of Western Australia</i>
1982-1984	<i>Guest Worker, Pulmonary Branch and Physician-in-Charge (on rotation) Clinical Service, Pulmonary Function Testing, Pulmonary Branch Clinical Center, National Institutes of Health Bethesda, Maryland, United States of America</i>
1979-81	<i>Sir Charles Gairdner Hospital, Perth, Western Australia</i>
1979	<i>Medical Registrar/General Medicine, Endocrinology, Renal Medicine</i>
1980	<i>Resistrar, Respiratory Medicine</i>
1981	<i>Senior Registrar, Respiratory Medicine and Postgraduate Medical Education.</i>
1977-1978	<i>Senior Registrar General Medicine, Geriatrics, Respiratory Guy's Hospital, London, United Kingdom.</i>
1976-1977	<i>Medical Registrar/Medical Assistant Chest Medicine, General Medicine</i>

1974-1975 Southend Hospital, Southend, Essex, United Kingdom.  
Full time course in Tropical Medicine and Hygiene  
September - December, 1976. University of Liverpool.  
Resident Medical Officer  
Royal Perth Hospital, Western Australia.  
General Medicine, Cardiology, Rheumatology, Neurology, Anaesthetics, Neurosurgery,  
Casualty, General Surgery  
term in Papua New Guinea.

#### 4. PROFESSIONAL/ADMINISTRATIVE

##### 4.1 Membership of Professional Societies

###### Australian

Thoracic Society of Australia and New Zealand  
Australian Society for Immunology  
Royal Australasian College of Physicians  
Clinical Oncology Society of Australia  
Cancer Research Association of Western Australia  
Australian Cytokine Research Association  
Cell Biology/Immunology Special Interest Group, Thoracic Society of Australia and New Zealand  
Cancer Foundation of Western Australia  
Australasian Gene Therapy Society  
Australian Lung Foundation

###### International

American Thoracic Society  
American College of Chest Physicians  
International Academy of Chest Physicians and Surgeons  
American Association for Cancer Research  
American Association of Immunologists  
International Society for Interferon and Cytokine Research  
International Association for the Study of Lung Cancer  
Royal College of Physicians (United Kingdom)  
British Thoracic Society  
British Society for Immunology  
International Mesothelioma Interest Group

###### Associated Medical Organisations

Christian Medical and Dental Fellowship  
Medical Association for the Prevention of War  
Amnesty International (Medical)

###### Other professional group

Mensa

##### 4.2 Administrative Committees

###### Current

Director, National Centre for Asbestos Related Diseases (NCARD). 2007 -  
Director, The Fathering Project. 2007 -  
Director, International Skills and Training Institute in Health (ISTIH). 2005 -  
Lung Cancer Consultative Group, Australian Lung Foundation. 2001 -  
Lung Cancer Group, WACOG. 2000 -  
Member, Senior Faculty, Western Australian Institute for Medical Research (WAIMR). 1998 -  
Board Member, Keogh Institute for Medical Research, 1996 -  
Convenor, Cell Biology and Immunology Special Interest Group, Thoracic Society of Australia and New Zealand. 1990 -

Member, University Department of Medicine Academic Staff. 1988 -  
Member, Department of Respiratory Medicine Consultant Staff Committee. 1984 -

#### Past

Chairman, State Health Research Advisory Council. 2005-2015  
NHMRC Research Committee 2003-2006.  
Australian Cancer Foundation for Medical Research, Medical Research Advisory Committee. 1993-2007.  
Chairman, NHMRC Asbestos Working Party 2002-2003.  
Member, Executive Board, WA Institute for Medical Research, 1997-2001.  
Member, Board of Directors, WA Institute for Medical Research, 1997-2001.  
Sir Charles Gairdner Hospital Research Advisory Committee, 1996-2001.  
Sir Charles Gairdner Hospital Site Committee, 1996-2001.  
UWA Faculty Appeals Committee 1993-2001.  
PMH Postgraduate Fellowships Committee 1993-2000.  
Member of the Division of Dentistry and Medicine Bachelor of Medical Science working party 1991- 2000.  
International Advisory Committee for the Annual International Meeting, American Thoracic Society 1991-1999.  
NH&MRC Regional Grants Interview Committee, 1998.  
Member of the Division of Dentistry and Medicine Equipment Advisory Committee 1991-1998.  
Member of Postgraduate Medical Education Committee of the Sir Charles Gairdner Hospital 1981, 1991-1998.  
Head of University Department of Medicine, Queen Elizabeth II Medical Centre Unit, 1996.  
Member, Department of General Medicine, 1988-1996.  
Member, Clinical Oncology Society of Australia Planning Committee for 1989/1993 Annual Scientific Meeting.  
UWA delegate to the Australian Medical Council National Workshop on Competency-based Skills Assessment in Medicine 1991.  
Programme Committee, Australian Society for Immunology Annual Scientific Meeting for 1991.  
Education subcommittee, Thoracic Society of Australia and New Zealand 1988-1991.  
Member, Medical and Scientific Advisory Committee, Asbestos Diseases Research Foundation 1989.  
Immediate Past President, Cancer Research Association of WA 1989.  
Lung Cancer Subgroup, Clinical Oncology Society of Australia. 1988-89.  
Inaugural President, Cancer Research Association of WA, 1988.  
Secretary of the Christian Medical Fellowship of Western Australia 1981.  
Member of the University of Western Australia Graduate Medical Association Executive (Secretary 1979/80, Committee member 1981).  
Editor of Graduate Medical Bulletin, UWA School of Medicine, 1973, 1979, 1980.

#### **4.3 External Journal Review Panels**

American Journal of Respiratory and Critical Care Medicine  
American Journal of Respiratory Cell and Molecular Biology  
Immunology and Cell Biology  
Australian and New Zealand Journal of Medicine  
Journal of Laboratory and Clinical Medicine  
Journal of Allergy and Clinical Immunology  
Thorax  
Journal of Immunology  
Nature Medicine  
Nature Immunology  
International Journal of Cancer  
Journal of Clinical Pathology

#### **4.4 Professional Research Body Peer Review Panels**

National Health and Medical Research Council of Australia  
- Project grants review panel 1985-

- Australian Fellowship Review Panel 2010
- Program Grants committee/interview panels 2003-2007
- Research Committee Member 2002-2006
- Clinical Research Advisory Group 2002-2006
- Regional Grants Interview Panel 1998

WA Telethon Foundation

Cancer Foundation of South Australia

Royal Adelaide Hospital Research Foundation

Cancer Foundation of Victoria

Thoracic Society of Australia and New Zealand

Adelaide Children's Hospital Research Foundation

Australian Cancer Foundation for Medical Research

WA Institute for Medical Research

Foundation for Advanced Medical Research

Member of the University of Western Australia Graduate Medical Association Executive (Secretary 1979/80, Committee member 1981). Editor, Graduate Medical Bulletin 1980, 1981.

## 5. INTERESTS

### Additional Medical Interests

Communication skills in medicine

Medical Ethics

Tropical Medicine and Public Health

### Other interests

#### **Football (Australian Rules)**

University Football Club from 1968.

Selected in All-Australian Intersvarsity Football Team, 1972 and 1973.

Reserves and League Football, Swan Districts Football Club, 1974.

Life Time Social Member, Swan Districts Football Club

Coach, University A-grade Colts Football Team (1981, 1985, 1986, 1987), Head Coach and A-grade Coach (1988, 1989). 3 premierships.

Clubman of the Year 1987.

Life member from 1989.

Member, Australian Coaching Association

### Languages spoken

Indonesian, French, Tok Pisin and Italian

#### **Cricket**

Played with Bassendean-Bayswater, University and Nedlands (Western Australia), Goroka (Papua New Guinea) and Southchurch (United Kingdom) Cricket Clubs.

Member, Western Australian Cricket Association.

Also windsurfing, music, hiking, computing and kayaking.

## 6. PUBLICATIONS

### 6.1 Published Books

1. Kradin RL, Robinson BWS. Immunopathology of Lung Disease. Butterworth-Heinemann, Boston. 1996. [ISBN: 0-7506-9282-0].
2. Robinson BWS, Chahinian P. Mesothelioma. Martin Dunitz. 2002. [ISBN:9-05823-180-1].
3. Robinson BWS. Fathering from the Fast Lane. Finch Publishing, Sydney. 2002. [ISBN:1-876451-21-1].
4. Robinson, Bruce. The Blue Book of Tips for Fathers and Father Figures. 2007. MACSIS Publishing, Perth. [ISBN 978-0-9805134-1-7].
5. Robinson, Bruce. Daughters and their Dads. 2008. MACSIS Publishing, Perth. [ISBN 978-0-9805134-0-0]
6. Robinson, Bruce. Fathering in the UK. MACSIS Publishing, Perth 2013. E-book
7. Robinson, Bruce. Dads Down Under. MACSIS Publishing, Perth 2013. E-book
8. Robinson, Bruce. FatheringUSA. MACSIS Publishing, Perth 2013. E-book

### 6.2 Published Case Reports and Letters

1. Robinson BWS. Henoch-Schonlein purpura due to food sensitivity. Br Med J 1977; 1: 510-511.
2. Robinson BWS, Corless D. Spurious polycythaemia resolving during observation. Br Med J 1978; 2: 280.
3. Robinson BWS. Medical screening of old people. The Lancet 1978; 2: 532.
4. Robinson BWS. Death from asthma. Med J Aust 1980; 1: 144.
5. Robinson BWS, Joske RA. Familial Mediterranean fever in Australia. Med J Aust 1980; 1: 494.
6. Robinson BWS. Bone-scanning in hypertrophic osteoarthropathy. Thorax 1980; 35:960.
7. Robinson BWS, Lewis RR. Myocardial metastasis from carcinoma of the pancreas presenting as acute myocardial infarction. Proc Roy Soc Med 1982; 75: 560-562.
8. Robinson BWS. Doctor in pain-learning as a patient. Med J Aust 1992;156:669.
9. Lee YC, Chew GT, Robinson BWS. Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis. Aust NZ J Med 1999, 29(6):843-4.
10. Robinson BWS, Lake RA. Malignant mesothelioma-reply. New England Journal of Medicine 354 (3):306-307 Jan 19 2006.
11. Takaro, TK, Davis D, Van Rensburg SJ, Robinson BW et al. Scientists appeal to Quebec Premier Charest to stop exporting asbestos to the developing world. Int J Occup Environ Health. 2010 Apr-Jun; 16 (2): 241-8.
12. Creaney J and Robinson BWS. Author's response: Inconsistent results or inconsistent methods? A plea for standardisation of biomarker sampling in mesothelioma studies. Thorax 2015 70 (4) 374-5.

### 6.3. Book Chapters

1. Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW. Malignant mesothelioma: studies of immunological anti-cancer processes. In G Peters, Ed. Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, chap 5. 1989. Garland Publishing Inc, New York. 153-172.
2. Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW. Evaluation of pulmonary inflammatory processes in asbestos-exposed individuals. In G Peters, Ed. Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, 1989. chap. 9 Garland Publishing Inc, New York. 277-296.
3. Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW. Malignant mesothelioma: studies of immunological anti-cancer processes. In "Asbestos Diseases Update", Chap. 4. Garland Publishing Inc, New York, 1989.
4. Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW. Pulmonary inflammation in asbestos-exposed individuals. In "Asbestos Diseases Update", Chap 1. Garland Publishing Inc, New York, 1989.
5. Robinson BWS, Manning LS, Christmas TI, Bowman RV, Davis MR, Musk AW. Immunotherapy of malignant mesothelioma: Studies using IL2/LAK cells and interferon alpha 2a. In Hersey P Ed. Biological Agents in the Treatment of Cancer. New South Wales Government Printing Office, Sydney, 1990; 414-423.

6. Robinson BWS. Organic dust disease; mediators and mechanisms. In: Rylander R and Musk AW (eds). Workshop on Health Effects of Grain and Other Organic Dusts, Committee on Organic Dusts, ICOH, 26-29 1991.
7. Robinson BWS, Bowman R, Christmas T, Musk AW, Manning LS. Immunotherapy for malignant mesothelioma: use of interleukin-2 and interferon alpha. *Interferons and Cytokines* 1991;18:5-7.
8. Whitaker DW, Manning LS, Robinson BWS, Shilkin K. The pathobiology of the mesothelium. In Henderson DW, Shilkin K, Langlois S, Whitaker D eds. *Malignant Mesothelioma*. 1992. Hemisphere Publishing Corp. New York. 25-68
9. Manning LS, Rose, AH, Bowman RV, Christmas TI, Garlepp MJ, Robinson BWS. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma. In Henderson DW, Shilkin K, Langlois S, Whitaker D, eds. *Malignant Mesothelioma*. 1992. Hemisphere Publishing Corp. New York. 278-291.
10. Garlepp MJ, Fitzpatrick D, Mutsaers S, Bielefeldt-Ohmann H, David M, Robinson BWS Mesothelioma: recent studies of growth regulation. In G Peters (ed): *Sourcebook on Asbestos Diseases*; vol 8, 1993 Garland publishing Inc, New York. 201-218.
11. Upham J, Musk AW, Robinson BWS. Mesothelioma: new therapeutic approaches. In G Peters (ed): *Sourcebook on Asbestos Diseases*; vol 8, 1993 Garland publishing Inc, New York. 191-200.
12. Robinson BWS. Immunobiology and immunotherapy of malignant mesothelioma. In: *Mesothelial Cell and Mesothelioma*, J Bignon, MC Jaurand (eds). *Lung Biology in Health and Disease*, Volume 78. New York 1994; 253-266.
13. Robinson BWS. Cell reactions and inflammation. In Rylander R, Jacobs RR, eds. *Handbook on Organic Dusts*. 1994, CRC Press, Boca Raton Florida, 95-107.
14. Robinson BWS, Venaille TJ, Musk AW. Effects of a selection of asthma-inducing occupational agents on human epithelial cells. In Research Report 1994-95. National Occupational Health & Safety Commission, Australian Govt. Printing Office, Canberra. 129-131.
15. Robinson BWS, Garlepp MJ, Scott B. Mesothelioma. In Crystal RG, West JB. Eds. *The Lung: Scientific Foundations*, Second Edition, 1995. Raven Press, New York 2599-2610.
16. Garlepp MJ, Davidson JA, Leong CC, Robinson BWS Gene therapy of malignant mesothelioma. In: *The internet book of gene therapy: cancer therapeutics*. Eds. Sobol RE, Scanlon KJ, Appleton & Lange, Norwalk, CT, pp 257-268, 1995.
17. Davidson JA, Robinson BWS. Mesothelioma. Stuart-Harris R, Penny R eds. In: *The Clinical Applications of the Interferons*, 1995:225-235.
18. Robinson BWS, Davidson JA, Garlepp MJ. The immunology and immunopathology of malignant mesothelioma. Kradin RL, Robinson BWS eds. In: *Immunopathology of lung disease*. Butterworth Heinemann, Stoneham, MA 1996:91-513.
19. McLennan G, Walsh RL, Robinson BWS. Bronchialveolar Lavage. Kradin RL, Robinson BWS eds. In: *Immunopathology of lung disease*. Butterworth Heinemann, Stoneham, MA 1996:529-540.
20. Robinson BWS, Sellner L, Redwood A, Leong CC, Davidson JA, Peroni DJ, Marzo AL, Garlepp MJ and Scot B. New techniques for evaluating lung immunology and immunopathology. Kradin RL, Robinson BWS eds. In: *Immunopathology of lung disease*. Butterworth Heinemann, Troneham, MA 1996:541-567.
21. Robinson BWS. Sarcoidosis, Kradin RL, Robinson BWS eds. In: *Immunopathology of lung disease*. Butterworth Heinemann, Stoneham, MA 1996:165-190.
22. Scott B, Mukherjee S, Lake R, Robinson BWS, *Malignant Mesothelioma*. In: *Textbook of Lung Cancer*. Ed Hanson H. London: Martin Dunitz; 2000.p.273-293.
23. Lee J, Robinson BWS. The history of mesothelioma in Australia 1945-2001. In: *Mesothelioma*. Robinson BWS, Chahinian PA, Editors. London: Martin Dunitz; 2002. p.55-86.
24. Lee YC, Thompson RI, Dean A, Robinson BWS. Clinical and palliative care aspects of malignant mesothelioma. In: *Mesothelioma*. Robinson BWS, Chahinian PA, Editors. London: Martin Dunitz; 2002. p.111-126.
25. Serman DH, Albelda SM, Mukherjee S, Robinson BWS. Gene therapy for malignant mesothelioma - "suicide gene" and immunological approaches. In: *Mesothelioma*. Robinson BWS, Chahinian PA, Editors. London: Martin Dunitz; 2002. p.223-234.
26. McLaren B, Robinson BWS. The molecular pathogenesis of mesothelioma. In: *Mesothelioma*. Robinson BWS, Chahinian PA, Editors. London: Martin Dunitz; 2002. p.307-323.
27. Mukherjee S, Robinson BWS. Immunotherapy of malignant mesothelioma. In: *Mesothelioma*. Robinson BWS, Chahinian PA, Editors. London: Martin Dunitz; 2002. p.325-338.

28. McLaren BR, Robinson BWS, Lake RA. Pathogenesis of mesothelioma. Text book of Respiratory cell and molecular biology. Wardlaw AJ and Hamid Q, Editors. London: Martin Dunitz; 2002. p.367-380.
29. Nelson D, Lake RA, Robinson BWS. Experimental models of mesothelioma. In: Textbook of Pleural Diseases. Eds. Light RW and Lee YCG; 2003. 167-179.
30. Nowak AK, Lake RA, and Robinson BWS. Immunotherapeutic approaches and vaccination strategies. In: Malignant Mesothelioma. Eds. Pass, Vogelzang, Carbone, 2005. 798-817.
31. Robinson BWS. Mesothelioma. in 'Encyclopedia of Respiratory Medicine' Geoffrey J. Laurent GJ, Shapiro S Eds. 2006. Elsevier. Oxford. 52-56.
32. Robinson BWS. Malignant Mesothelioma. In: Encyclopaedia of Respiratory Medicine. Eds. Laurent GJ, Shapiro SD. Elsevier Ltd. 2006, 52-56.
33. Nelson D, Robinson C, Dunham MA, Robinson BWS. Malignant Mesothelioma. In: Environmental and Occupational Medicine. Eds. Rom WN, Markowitz SB, 2007. 317-329.
34. Smith AM, Lansley S, Jackaman C, Koloska B, Broomfield S, Robinson BWS, Nelson DJ. Immunobiology of Malignant Mesothelioma (MM). In: Malignant Pleural Mesothelioma. Eds. O'Byrne K, Rusch V. Oxford University Press, USA, 2007.
35. Creaney J, Robinson BWS. Possible Roles for Soluble Mesothelin-Related Proteins as Tumour Markers for Malignant Mesothelioma. In: Mesothelioma from bench to clinic. Editor: Alfonso Baldi, 2007 Nova Science Publishers Inc.
36. Robinson BWS, Lake R, Robinson C, Creaney J. Malignant Mesothelioma In: Textbook of Lung Cancer. 2nd Edition. Ed. Hanson H. London: Dunitz M. 2008.
37. Broaddus VC, Robinson BWS. Tumors of the Pleura. Murray and Nadel's Textbook of Respiratory Medicine, 5th ed. 2010. Ch 75. Elsevier.
38. Robinson B, Baas P, Kindler HL. Malignant Mesothelioma. In: Principles and Practice of Lung Cancer. Harvey I. Pass, David P Carbone, David H Johnson Eds. Walters Kluwer. 2010. Philadelphia.
39. Robinson BWS and Meniawy T. Malignant Pleural Mesothelioma. In: Clinical Respiratory Medicine 4<sup>th</sup> edition. Eds. Spiro S, Silvestri G and Agusti A. Elsevier 2012.
40. Lotze MT, Robinson B, June CH, Whiteside TL. Tumor Immunotherapy. In: Clinical Immunology 4<sup>th</sup> edition. Eds. Rich R, Fleisher T, Shearer W, Schroeder H, Frew A and Weyand C. Elsevier 2012.
41. Broaddus VC and Robinson BWS Pleural Tumors. Vol 2, Section N, Chapter 82, pp1461-1477.. In: Murray and Nadel's Textbook of Respiratory Medicine 6<sup>th</sup> Edition Eds Broaddus VC, Mason RJ, Ernst JD et al. Elsevier Saunders. Philadelphia 2016.

#### 6.4 Papers

1. Robinson BWS, Musk AW. Benign asbestos pleural effusion diagnosis and course. Thorax 1981; 36: 896-900.
2. Robinson BWS. Nitrofurantoin induced interstitial pulmonary fibrosis. Med J Aust 1983; 1: 72-76.
3. Robinson BWS, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest 1984; 74: 942-50.
4. Venet A, Hance AJ, Saltini C, Robinson BWS, Crystal RG. Enhanced alveolar macrophage-mediated antigen induced T lymphocyte proliferation in sarcoidosis. J Clin Invest 1985; 75: 293-301.
5. Robinson BWS, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985; 75: 1488-1495.
6. Robinson BWS, Rose AH, Hey A, Whitaker D, Musk AW. Alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite- and chrysotile-exposed individuals. Chest 1986; 90: 396-402.
7. Holt P, Robinson BWS, Reid M, Kees U, Warton A, Dawson V, Rose AH, Schon-Hegrad M, Papadimitrou J. Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic digestion procedure. Clin Exp Immunol 1986; 66: 188-200
8. Robinson BWS, Morstyn G. Interleukin-2-activated Natural Killer cells are active against lung cancer cells. Chest 1987; 91: 31-32.
9. Robinson BWS, Rose A, Thompson PJ, Hey A. Comparison of bronchoalveolar lavage helper/suppressor T-cell ratios in sarcoidosis versus other interstitial lung diseases. Aust NZ J Med 1987; 17: 9-15.



10. Robinson BWS, Morstyn G. Natural killer (NK)-resistant human lung cancer cells are lysed by recombinant interleukin-2-activated NK cells. *Cell Immunol* 1987; 106: 215-222.
11. Robinson BWS, James A, Rose A, Sterret G, Musk AW. Bronchoalveolar lavage sampling of airway and alveolar cells. *Br J Dis Chest* 1988; 82: 45-55.
12. Robinson BWS, Rose AH, Hayes A, Musk AW. Increased pulmonary gamma interferon production in asbestosis. *Am Rev Respir Dis* 1988; 138: 278-283.
13. Robinson BWS. Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung diseases. *Thorax* 1988; 43: 508-515
14. Holt PG, Kees UR, Schon-Hegrad MA, Rose A, Ford J, Bilyk N, Bowman R, Robinson BWS. Limiting dilution analysis of T cells extracted from solid human lung tissue: comparison of precursor frequencies for proliferative responses and lymphokine production between lung and blood T cells from individual donors. *Immunology* 1988; 64: 649-654.
15. Hayes A, Rose AH, Musk AW, Robinson BWS. Neutrophil chemotactic factor release and neutrophil alveolitis in asbestos-exposed individuals. *Chest* 1988; 94: 521-525.
16. Warton A, Papadimitriou JM, Venaille TJ, Mendis SHW, Robinson BWS. Human amnion membrane as a model for studying the host-parasite relationship in trichomoniasis. *Int J Parasitol* 1988; 18: 1003-1005.
17. Robinson BWS, Kees UR, Holt PG. Lung interstitial natural killer cells in patients with lung cancer: presence, activity and response to interleukin-2. *Lung Cancer* 1989; 5: 41-48.
18. Hayes A, Mullan B, Lovegrove FT, Robinson BWS, Musk AW. Gallium lung scanning and bronchoalveolar lavage in crocidolite-exposed workers. *Chest* 1989; 96: 22-26.
19. Manning L, Bowman RV, Darby SB, Robinson BWS. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. *Am Rev Respir Dis*, 1989; 139: 1369-1374.
20. Gibson PG, Robinson BWS, McLennan G, Bryant DH, Breit SN. The role of bronchoalveolar lavage in the assessment of diffuse lung diseases. *Aust NZ J Med* 1989; 19: 281-291
21. Robinson BWS. Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibres but can be restored by recombinant interleukin-2. *Am Rev Respir Dis*, 1989; 139: 897-901.
22. Venaille T, Mendis A, Warton A, Walker L, Papadimitriou J, Robinson BWS, Study of human epithelial cell detachment and damage: development of a model. *Immunol Cell Biol* 1989; 67: 359-369.
23. Phillips MJ, Venaille TJ, Mendis AHW, Thompson PJ, Robinson BWS Effect of nedocromil sodium on neutrophil and eosinophil-induced epithelial cell desquamation in a human in vitro epithelial model. *Drugs* 1989; 37: 56-62.
24. Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BWS. Indomethacin augments lymphokine-activated killer cell generation by patients with malignant mesothelioma. *Clin Immunol and Immunopath* 1989; 53: 68-77.
25. Mendis AHW, Venaille T, Robinson BWS. Study of human epithelial cell detachment and damage: effects of proteases and oxidants. *Immunol and Cell Biol* 1990; 68:95-105.
26. Hayes A, Venaille TJ, Rosse AH, Musk AW, Robinson BWS. Asbestos-induced release of a human alveolar macrophage-derived neutrophil chemotactic factor. *Exp Lung Res* 1990;16(2):121-130.
27. Robinson BWS, Rose AH. Pulmonary  $\gamma$  interferon production in patients with fibrosing alveolitis. *Thorax* 1990;45:105-108.
28. Flexman J, Manning L, Robinson BWS. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: Comparison of systemic, intrapleural and inhalation routes. *Clin Exp Immunol* 1990; 82:151-156.
29. Robinson BWS, Venaille TJ, Mendis AHW, McAleer R. Allergens as proteases: an aspergillus fumigatus proteinase directly induces human epithelial cell detachment. *J Allergy Clin Immunol* 1990; 86:726-731.
30. Robinson BWS. After the Fellowship - basic research *Med J Aust* 1990;153:692-696
31. Bowman R, Manning LS, Davis M, Robinson BWS Capacity of tumour necrosis factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma. *Clin Immunol Immunopath* 1991;58:80-91
32. Manning LS, Murch A, Garlepp MJ, Davis MR, Musk A, Robinson BWS. Establishment and characterisation of five human malignant mesothelioma cell lines derived from pleural effusions. *Int J Cancer* 1991;47:285-290

33. Manning L, Davis M, Robinson BWS Asbestos fibres inhibit the in vitro activity of lymphokines-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma. *Clin Exp Immunol* 1991;83:85-91.
34. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp M. HLA antigen expression and malignant mesothelioma. *Am J Resp Cell Mol Biol.* 1991;5:213-220.
35. Bowman R, Whitaker D, Manning LS, Davis MR, Robinson BWS Interaction between Dactinomycin and tumor necrosis factor in mesothelioma - cachexia without oncolysis. *Cancer* 1991;67:2495-2500.
36. Bowman R, Manning LS, Davis MR, Robinson BWS Chemosensitivity and cytokine sensitivity of malignant mesothelioma. *Cancer Chemother Pharmacol* 1991; 28:420-426.
37. Robinson BWS, Sterrett G. Bronchiolitis obliterans associated with polyarteritis nodosa. *Chest* 1992 102:309-311
38. Robinson BWS. Doctor in pain - learning as a patient. *Med J Aust* 1992 156:355-357
39. Robinson BWS, Venaille T, Blum R, Mendis AH. Eosinophils and major basic protein damage but do not detach human amniotic epithelial cells. *Exp Lung Res* 1992;18:583-593
40. Holt PG, Clough JB, Holt BJ, Baron-Hay MJ, Rose AH, Robinson BWS Thomas WR. Genetic 'risk' for atopy is associated with delayed postnatal maturation of T-cell competence. *Clin Exp Allergy* 1992;22:1093-99.
41. Davis MR, Manning LS, Whitaker D, Robinson BWS. Establishment of a murine model of malignant mesothelioma. *Int J Cancer* 1992 52:881-886.
42. Garlepp MJ, Rose AH, Bowman RV, Mavaddat N, Dench J, Holt BJ, Baron-Hay M, Holt PG, Robinson BWS. A clonal analysis of lung T cells derived by bronchoalveolar lavage of healthy individuals. *Immunology* 1992 77:31-37.
43. Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BWS. Effect of Interferon  $\alpha$ -2a on malignant mesothelioma. *J Interferon Res* 1993;13:9-12.
44. Manning LS, Davis MR, Bielefeldt-Ohmann H, Marzo AL, Garlepp MJ, Whitaker D, Robinson BWS Evaluation of immunogenicity of murine mesothelioma cells by immunization. *Europ Resp Rev* 1993;3(11):234-237.
45. Robinson BWS, Bowman RV, Manning LS, Musk AW, Van Hazel GA. Interleukin-2 and lymphokine-activated killer cells in malignant mesothelioma. *Europ Resp Rev*; 1993; 3(11):220-222.
46. Garlepp MJ, Christmas TI, Manning LS, Davis MR, Robinson BWS Constitutive and inducible HLA antigen expression in malignant mesothelioma. *Europ Resp Rev* 1993 3:11:231-233.
47. Garlepp MJ, Christmas TI, Mutsaers SE, Manning LS, Davis M, Robinson BWS Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. *Europ Resp Rev* 1993; 3(11):192-194.
48. Garlepp MJ, Christmas TI, Manning LS, Mutsaers S, Dench J, Leong C, Robinson BWS. The role of platelet-derived growth factor in the growth of human malignant mesothelioma. *Eur Respir Rev* 1993;3(11):189-191.
49. Robinson BWS, Manning LS, Bowman RV, Christmas TI, Musk AW, Davis MR, Bielefeldt-Ohmann H, Upham J, Garlepp MJ. The scientific basis for the immunotherapy of human malignant mesothelioma. *Europ Resp Rev* 1993;3(11):195-198.
50. Mavaddat N, Robinson BWS, Rose AH, Manning LS, Garlepp MJ. An analysis of the relationship between  $\gamma\delta$  T cell receptor V gene usage and non-major histocompatibility complex-restricted cytotoxicity. *Immunol & Cell Biol* 1993 71:27-37.
51. Davis M, Manning LS, Whitaker D, Garlepp MJ, Robinson BWS A murine model of mesothelioma. *Eur Respir Rev* 1993;3(11):116-117.
52. Robinson BWS. Development of new therapeutic strategies for mesothelioma. *Lung Cancer* 1993;9:413-418.
53. Upham JW, Musk AW, van Hazel G, Byrne M, Robinson BWS. Interferon alpha and doxorubicin in malignant mesothelioma. *Aust NZ J Med* 1993;23:683-687.
54. Robinson BWS. Immunotherapy strategies in patients with mesothelioma. *Cancer Forum* 1993;17:106-111.
55. Venaille TJ, Musk AW, Robinson BWS. Direct effects of selected occupational asthma-inducing agents on human epithelial cells. *J Occup Health Safety* 1993;9:435-446.

56. Richardson DR, Cameron K, Robinson BWS, Turner KJ. The mechanisms of IgE uptake by human alveolar macrophages and a human B-lymphoblastoid cell line (Wil-2wt). *Immunology* 1993;79:305-311.
57. Christmas TI, Manning LS, Mutsaers SE, Dench J, Leong C, Robinson BWS Garlepp MJ. Platelet-derived growth factor as an autocrine factor in murine malignant mesothelioma. *Eur Respir Rev* 1993;3(11):192-194
58. Garlepp MJ, Dench JE, Rose AH, Robinson BWS Clonal analysis of lung and blood T cells in patients with sarcoidosis. *Thorax* 1994;49:577-585.
59. Upham JW, McMenamin C, Schon-Hegrad MA, Robinson BWS ,Holt PG. Functional analysis of human bronchial mucosal T cells extracted with Interleukin-2. *Am J Respir Crit Care Med* 1994;149:1608-1613.
60. Venaille TJ, Misso NLA, Phillips MJ, Robinson BWS,Thompson PJ. Effects of different density gradient separation techniques on neutrophil function. *Scand J Clin Lab Invest* 1994;54:385-391.
61. Leong C, Robinson BWS , Garlepp M. Generation of an antitumor immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. *Int J Cancer* 1994;59:212-216.
62. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma. *Growth Factors* 1994;11:29-44.
63. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BWS. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leukocytes and cytokine production in a murine model. *Cancer Immunol, Immuno* 1994;39:347-359.
64. Upham J, Garlepp MJ, Musk AW, Robinson BWS. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. *Thorax* 1995;50:887-893.
65. Venaille TJ, Mendis AHW, Phillips MJ, Thompson PJ, Robinson BWS. Role of neutrophils in mediating human epithelial cell detachment from native basement membrane. *J Allergy Clin Immunol* 1995;95; 597-606.
66. Staton JM, Dench JE, Currie B, Fitzpatrick DR, Himbeck R, Allen R, Bruce J, Robinson BWS, Bielefeldt-Ohmann H. Expression and immune recognition of stress proteins in sarcoidosis and other chronic interstitial lung diseases. *Immunol Cell Biol* 1995; 73:23-32.
67. Upham JW, Strickland DH, Bilyk N, Robinson BWS, Holt PG. Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion. *Immunol* 1995; 84:142-147.
68. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Musk AW, Robinson BWS. Potential for Interferon- $\alpha$ -based therapy in mesothelioma: assessment in a murine model. *J Interferon Cytokine Res* 1995; 15:213-223.
69. Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BWS,Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. *Cancer Immunol, Immuno* 1995; 40:241-250.
70. Fitzpatrick DR, Manning LS, Musk AW, Robinson BWS, Bielefeldt-Ohmann H. Potential for cytokine therapy of malignant mesothelioma. *Cancer Treatment Rev* 1995;21:273-288.
71. Upham JW, Holt BJ, Baron-Hay MJ, Yabuhara A, Hales BJ, Thomas WR, Loh RKS, O'Keefe P, Palmer L, LeSouef P, Sly PD, Burton PR, Robinson BWS, Holt PG. Inhalant allergen-specific T cell reactivity is detectable in close to 100% of atopic and normal individuals: covert responses are unmasked by serum-free medium. *Clin Exp Allergy* 1995;24:634-642.
72. Jarnicki AG, Fitzpatrick DR, Robinson BWS, Bielefeldt-Ohmann H. Altered CD3 chain and cytokine gene expression in tumour infiltrating T lymphocytes (TIL) during the development of mesothelioma. *Cancer Lett* 1996;103:1-9.
73. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. Induction and maintenance of T cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression. *Cancer Gene Therapy* 1996; 3:321-330.
74. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma. *International J Cancer* 1996;71:476-482.
75. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ. The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer. *Immunol and Cell Biol* 1997;75; 356-359.

76. Marzo AL, Fitzpatrick DR, Robinson BWS , Scott B., Antisense oligonucleotides specific for transforming growth factor  $\alpha 2$  inhibit the growth of malignant mesothelioma both in vitro and in vivo. *Cancer Research* 1997; 57:3200-3207.
77. Upham JW, Strickland DH, Robinson BWS, Holt PG. Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages. *Thorax* 1997; 52:786-795.
78. Venaille TJ, Ryan G, Robinson BWS. Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum. *Resp Med* 1998;92; 233-240.
79. Davidson JA, Musk AW, Wood Baker R, Morey S, Ilton M, Yu LL, Drury P, Shilkin K, Robinson BWS. Intralesional cytokine therapy in cancer; A pilot study of GM-CSF infusion in mesothelioma. *J Immunotherapy* 1998; 21:389-398.
80. Robinson BWS, Mukherjee S, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi I, Scott B. Cytokine gene therapy or infusion as treatment for solid human cancer. *J Immunotherapy* 1998; 21(3):211-217.
81. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BWS. Interleukin-12 induces an effective anti-tumour response in malignant mesothelioma. *Am J Resp Cell Mol Biol* 1998; 19(5):738-46.
82. Robinson C, Robinson BWS, Lake RA. Sera from patients with malignant mesothelioma contain autoantibodies. *Lung Cancer*. 1998; 20(3):175-84.
83. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BWS. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. *J Clin Onc* 1999; 17:25-30.
84. Lake RA, Robinson BWS, Hayball JD. MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. *Immunol Cell Biology*. 1999 77(1):99-104.
85. Marzo AL, Lake RA, Robinson BWS Scott B T-Cell Receptor Transgenic Analysis of Tumor-specific CD8 and CD4 responses in the eradication of solid tumours. *Cancer Res*. 1999; 59:1071-1079.
86. Pass HI, Robinson BWS, Testa JR, Carbone M. Emerging translational therapies for mesothelioma. *Chest* 1999;116:455S-460S
87. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BWS, Scott B. Tumor antigens are constitutively presented in the draining lymph nodes. *J Immunol* 1999; 162:5838-5845.
88. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BWS, Scott B. Cytokine gene therapy of mesothelioma: Immune and anti-tumor effects of transfected IL12. *Am J Resp Cell Mol Biol*. 1999, 21(3):347-356.
89. Robinson BWS, Lake RA, Nelson DJ, Scott BA, Marzo AL. Cross-presentation of Tumour Antigens - Evaluation of Threshold, Duration, Distribution and Regulation. *Immunol. Cell Biol*. 1999;77:552-558.
90. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson BWS. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. *Cancer Gene Therapy*. 2000,7(5):663-670.
91. Robinson C, Callow M, Stevenson S, Scott B, Robinson BWS, Lake RA. Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities. *Am J. Respir. Cell Mol. Biol*. 2000;22:550-556.
92. McLaren BR, Robinson BWS, Lake RA. New chemotherapeutics in malignant mesothelioma: Effects on cell growth and IL6 production. *Cancer Chemother Pharmacol*. 2000;45(6):502-508.
93. Robinson BWS, Erle DJ, Jones DA, Shapiro S, Metzger WJ, Albelda S, Parks WC, Boylan A. Recent advances in molecular biological techniques and their relevance to pulmonary research. *Thorax* 2000; 55:329-339.
94. McLaren BR, Haenel T, Stevenson S, Mukherjee S, Robinson BWS, Lake RA. SV40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas. *Aust NZ J Med*. 2000; 30(4):450-456.
95. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BWS, Scott B. Tumor-Specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumour immunity. *J Immunol*. 2000;165(11):6047-6055.
96. Nelson DJ, Bundell C, Robinson BWS. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes. *J Immunol*. 2000; 165:6123-6232.

97. Robinson BWS, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL. Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance. *Clin Cancer Res.* 2001; 7(3 Suppl):811s-817s.
98. Robinson BWS, Robinson C, Lake R. Localised spontaneous mesothelioma regression in mesothelioma - probable immunological mechanism. *Lung Cancer.* 2001;32(2):197-201.
99. Creaney J, McLaren BM, Musk AW, de Klerk N, Robinson BWS, Lake RA. P53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. *BJ Cancer.* 2001;84(1):52-56.
100. Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson BWS. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. *J Immunol.* 2001;166:5557-5566.
101. Mukherjee S, Nelson DJ, Loh S, van Bruggen I, Palmer LJ, Leong C, Garlepp MJ, Robinson BWS The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor. *Cancer Gene Therapy.* 2001;8:580-588.
102. Robinson C, Callow M, Stevenson S, Robinson BWS, Lake RA. Private specificities can dominate the humoral response to self antigens in patients with cryptogenic fibrosing alveolitis. *Respiratory Research.* 2001; 2:119-124.
103. McLaren B, Whitaker D, Robinson BWS , Lake RA. Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma. *Cancer Chemother Pharmacol.* 2001;48(1):1-8.
104. Nowak A, Robinson BWS & Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. *Cancer Research.* 2002; 62(8) 2353-2358.
105. Nowak A, Lake RA, Kindler HL, Robinson BWS New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. *Seminars in Oncology.* 2002 Feb;29(1):82-96.
106. Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BWS. A multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma. *British Journal of Cancer.* 2002; 87:491-496.
107. Nowak AK, Lake RA, Marzo AL, Scott B, Heath RW, Collins EJ, Frelinger JA, Robinson BWS. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T-cells. *J Immunol.* 2003; 170:4905-4913.
108. Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BWS, Nelson DJ. Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine interleukin-12. *Cancer Gene Therapy.* 2003;10:591-602.
109. Nowak AK, Robinson BWS, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. *Cancer Research.* 2003; 63:4490-4496.
110. Jackaman C, Bundell C, Kinnear B, Smith A, Filion ,P, van Hagan, Robinson BWS D.Nelson Interleukin-2 intra-tumoral immunotherapy enhances CD8+ cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. *J Immunol.* 2003;171:5051-5063.
111. Nowak AK, Lake RA, Marzo AL, Scott B, Heath RW, Collins EJ, Frelinger JA, Robinson BWS. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T-cells. *J Immunol.* 2003; 170:4905-4913.
112. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Mesothelin-family proteins and diagnosis of mesothelioma. *Lancet.* 2003 Nov 15; 362(9396):1612-6.
113. Hayball JD, Robinson BWS, Lake RA. CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells. *Imm Cell Biol.* 2004 Apr;82(2):103-11.
114. Robinson BWS. *Soluble mesothelin-related protein - a sensitive new marker for mesothelioma. Am J Oncol Rev.* 2004;3:230-233.

115. Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, Robinson BWS. Current chemotherapeutic treatment of malignant pleural mesothelioma. *Expert Opinion in Pharmacotherapy*. 2004;5(12):2441-2449.
116. Robinson BWS, Edwards MG. Climbing Mount Kilimanjaro in a Blizzard. *Med J Aust*. 2004;181(11/12): 646-648.
117. Stumbles PA, Himbeck R, Frelinger JJ, Lake RA, Robinson BWS. Cutting edge: Tumour-specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate Tumor Regression following Systemic CD40 Activation. *J Immunol*. 2004;173:5923-5928.
118. Robinson BWS, Musk AW, Lake RA. Malignant Mesothelioma. *The Lancet*. 2005 366:397-408.
119. Lake RA, Robinson BWS. Immunotherapy and chemotherapy- a practical partnership. *Nature Rev Cancer*. 2005;5:397-405.
120. Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein - A blood test for mesothelioma. *Lung Cancer* 2005 49: S109-S111.
121. Creaney J, Robinson BWS, Detection of mesothelioma in asbestos exposed individuals: The potential role of soluble mesothelin related protein. *Seminars in Haematology-Oncology*. 2005 19:1025-40.
122. van der Most, R.G., Robinson BWS, and Lake, R.A., Combining Immunotherapy With Chemotherapy to Treat Cancer. *Discovery Medicine* 2005; 5:265-70.
123. Nelson DJ, Robinson BWS , Allan J, Van der Most R. Gene therapy of mesothelioma. *Expert Opin Biol Ther*. 2005, 8:1039-49.
124. van Bruggen I, Nelson DJ, Currie AJ, Jackaman C, Robinson BWS. Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. *J Immunother*. 2005 Jul-Aug;28(4):359-67.
125. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BWS , Lake RA. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. *Cancer Res*. 2005 Sep 1;65:7580-4
126. Robinson BWS, Lake RL. Advances in Malignant Mesothelioma. *New Eng J Med* 2005;353:1591-603.
127. Bundell CS, Jackaman C, Suhrbier A, Robinson BWS, Nelson DJ. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. *Cancer Immunol Immunother*. 2006 Aug;55(8):933-47.
128. Van der Most RG, Currie A, Robinson BWS, Lake RA, Cranking the immunologic engine with chemotherapy: Using context to drive tumour antigen cross-presentation towards useful anti tumour immunity. *Cancer Research* 2006 Jan 15 66(2):601-4
129. Van der Most RG, Robinson BWS, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years *Cancer Gene Therapy* 2006 Jan 27; 1-8.
130. Zhong J, Gencay-Cornelson MM, Bubendorf L, Burgess JK, Parson H, Robinson BWS, Tamm M, Black JL, Roth M. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP and TIMP and affect cell migration: a comparison between mesothelioma and mesothelial cells. *Journal of Cellular Physiology* 2006 May; 207(2):540-52.
131. Powell A, Creaney J, Broomfield S, van Bruggen I, Robinson BWS, Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. *Lung Cancer*, 2006 Mar 22; 52,189-197.
132. Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. *Clinical Cancer Res*. 2006 Sep 1; 12 (17):5129-35.
133. Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? *Adv Drug Deliv Rev*. 2006 Oct 1;58(8):975-90.
134. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, Robinson BW, Lake RA. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. *Cancer Res*. 2006 Nov 15;66(22):10786-94.
135. Creaney J, Christansen H, Lake RA, Musk A.W, de Klerk N, Robinson BWS. Soluble mesothelin related protein in mesothelioma. 2006 *Journal of Thoracic Oncology*. 2;172-174.

136. Diyagama DS, Lake RA, Robinson BWS, Creaney J, Bowtell DDC, Holloway AJ. An integrated analysis of chromosomal alteration and gene expression in malignant mesothelioma. *Lung Cancer* 2006;54: 523.
137. Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand M-C, Kjaerheim K, Pass HI, Robinson BWS, Tsao A. Eighth International Mesothelioma Conference. *Oncogene*. 2007 Oct 25;26(49):6959-67.
138. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BWS. Soluble mesothelin in effusions - a useful tool for the diagnosis of malignant mesothelioma. *Thorax*. 2007 Jul;62(7):569-76.
139. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. *Chest*. 2007 Oct;132(4):1239-46.
140. Van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. *Cell Death Differ*. 2008 Jan; 15(1):13-20.
141. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. *Br J Cancer*. 2008;98(9):1562-9.
142. Nelson D, Jackaman C, Robinson BWS, et al. Targeting the tumor microenvironment: A novel immunotherapy that cures large mesothelioma tumors by engaging neutrophils, CD8+T cells and tumor blood vessels. *Lung Cancer* 2008;54:12.
143. Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. Targeting the Effector Site with IFN- $\alpha$  $\beta$ -Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors. *J Immunol*. 2008 Feb 1;180(3):1535-44.
144. Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust-diseases board cohort study. *Am J Respir Crit Care Med*. 2008;178(8):832-7.
145. Creaney J, Yeoman, D, Demelker, Y, Segal A, Musk, AW, Skates, SJ, Robinson BWS. Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. *Journal of Thoracic Oncology* 2008 Aug; 3:8, 851-57.
146. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. *Int Immunol*. 2008;20(11):1467-79.
147. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer*. 2008; 61(2):235-43.
148. Jackaman C, Cornwall S, Robinson BWS, Lew AM, Zhan Y, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+CD25+Treg cells. *European Respiratory Journal*. 2009; 34: 162-175.
149. van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. *Cancer Immunol Immunother*. 2009 58 (8).
150. Creaney J and Robinson BWS. Serum and pleural fluid biomarkers for mesothelioma. *Current Opinion in Pulmonary Medicine* 2009 15:366-370. (Review).
151. Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. *J Immunol*. 2009;183(12):7898-908.
152. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. *PLoS One*. 2009; Sep 4(9):e6982.
153. Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. *J Immunol*. 2009 May;182(9):5217-24.

154. Park EK, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. *Clin Chem Lab Med*. 2010 Jun;48(6):869-74.
155. McDonnell AM, Prosser AC, van Bruggen I, Robinson BWS, Currie AJ. [CD8 \$\alpha\$ <sup>+</sup> DCs are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor](#). *European Journal of Immunology* 2010; 40 (6): 1617-1627.
156. Kurts C, Robinson BWS, Knolle PA. Cross-priming in health and disease. *Nature Reviews Immunology* 2010 10 (6): 403-414.
157. Creaney J, Musk AW, Robinson BW. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. *J Thorac Oncol*. 2010 Sep;5(9):1461-6.
158. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev*. 2010 Sep;19(9):2238-46.
159. Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. *Oncogene*. 2010 29, 6301-6313.
160. McDonnell AM, Robinson BW, Currie AJ. Tumour antigen cross-presentation and the dendritic cell: where it all begins? *Clin Dev Immunol*. 2010;2010:539519. (Review).
161. Creaney, J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumour volume, clinical stage and changes in tumour burden. *Clin Cancer Res*. 2011 Mar 1; 17(5): 1181-9.
162. Robinson B, Alatas MF, Robertson A, Steer H. Natural Disasters and the Lung Respiriology. 2011 Apr 16(3): 386-395.
163. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function - analysis of relationship and implications for mesothelioma screening. *Lung Cancer*. 2011 Sep; 73(3): 320-4.
164. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma- Which is best? *Lung Cancer*. 2011 Oct; 74(1): 55-60.
165. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, Nakano T, Pass HI, Robinson BW, Rusch VW, Sugarbaker DJ, van Zandwijk N. The MARS feasibility trial: conclusions not supported by data. *Lancet Oncology* 2011 Nov; 12 (12): 1093-4.
166. Creaney J, Dick Ian M, Yeoman D, Wong S, Robinson BWS. Auto-antibodies to  $\beta$ -F1-ATPase and Vimentin in Malignant Mesothelioma. *PlosOne* 2011 Oct 6 (10) e26515..
167. Hollevoet K, Reitsma JB, van Meerbeeck JP, Baas P, Creaney J, Cristaudo A, Di Serio F, Grigoriu D, Muley T, Nackaerts K, Pass HI, Rai AJ, Robinson BW, Rodriguez Portal JA, Scherpereel A, Schneider J, Tomasetti M. Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-Analysis. *Journal of Clinical Oncology*. 2012 30 (13): 1541-1549. (Review).
168. Park EK, Yates DH, Creaney J, Thomas, PS, Robinson BW and Johnson AR. Association of Biomarker Levels with Severity of Asbestos-Related Diseases. *Safety and Health at Work* 2012 3: 17-21.
169. Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JB, Armstrong NJ, Vallely MP, Musk AW, Robinson BWS, McCaughan BC, Klebe S, Mutsaers SE, van Zanwijk N, Reid G. Increased Circulating miR-625-3p A Potential Biomarker for Patients with Malignant Pleural Mesothelioma. *Journal of Thoracic Oncology*. 2012. Jul; 7 (7): 1184-91.
170. Khong A, Nelson D, Nowak A, Lake R and Robinson BWS. The use of agonistic anti-CD therapy in treatments for cancer. *International Reviews of Immunology*. 2012.Aug 31(4): 246-66.
171. McDonnell AM, Currie AJ, Brown M, Kania K, Wylie B, Cleaver A, Lake R and Robinson BWS. Tumor cells, rather than dendritic cells, deliver antigen to the lymph node for cross-presentation. *Oncoimmunology* 2012;1:7, pp 1-7 Oct.
172. Jackaman C, Lansley S, Allan JE, Robinson BW, Nelson DJ. IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. *Int Immunol*. 2012 Jun;24(6):357-68.
173. Brown MD, van Der Most R, Vivian JB, Lake RA, Larma I, Robinson BWS, and Currie AJ. Loss of Antigen Cross-Presentation After Complete Tumour Resection is Associated with the Generation of Protective Tumour-Specific CD8<sup>+</sup> T Cell Immunity. *Oncolimmunology* 2012 1 Oct; 1(7): 1084-1094.



174. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. *Clin Dev Immunol*. 2012;2012:656340. (Review).
175. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, Musk AW, Nowak AK, Robinson BW, Creaney J, A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. *Pathology* 2013 Jan 45 (1) 44-8.
176. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer* 2013 Apr; 80(1): 39-44.
177. Matullo G, Guarrera S, Betti M, Fiorito G, Ferrante D, Voglino F, Cadby G, Di Gaetano C, Rosa F, Russo A, Hirvonen A, Casalone E, Tunesi S, Padoan M, Giordano M, Aspesi A, Casadio C, Ardisson F, Ruffini E, Betta PG, Libener R, Guaschino R, Piccolini E, Neri M, Musk AW, de Klerk NH, Hui J, Beilby J, James AL, Creaney J, Robinson BW, Mukherjee S, Palmer LJ, Mirabelli D, Ugolini D, Bonassi S, Magnani C, Dianzani I. Genetic variants associated with increased risk of malignant pleural mesothelioma: a genome-wide association study. *PLoS One*. 2013 Apr 23;8(4):e61253.
178. Lesterhuis WJ, Salmons J, Nowak AK, Rozali EN, Khong A, Dick IM, Harken JA, Robinson BW, Lake RA. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. *Plos One*. 2013 Apr 23;8(4):e61895.
179. Cadby G, Mukherjee S, Musk AW, Reid A, Garlepp M, Dick I, Robinson C, Hui J, Fiorito G, Guarrera S, Beilby J, Melton PE, Moses EK, Ugolini D, Mirabelli D, Bonassi S, Magnani C, Dianzani I, Matullo G, Robinson BW, Creaney J, Palmer LJ. A genome-wide association study for malignant mesothelioma risk. *Lung Cancer*. 2013 Oct 82 (1): 1-8.
180. Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates S, Robinson BWS. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor as biomarkers for mesothelioma in pleural effusions and serum. *Disease Markers*. 2013 Aug 35 (2) pp 119-27.
181. Khong A, Brown MD, Vivian JB, Robinson BWS, Currie AJ. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model. *Journal of Immunotherapy*, 2013 Sep 36 (7) 365-72.
182. Creaney J, Dick IM, Segal A, Musk AW and Robinson BWS. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. *Lung Cancer*, 2013 Dec 82 (3):491-498.
183. Cleaver AL, Bhamidipaty K, Wylie B, Connor T, Robinson C, Robinson BW, Mutsaers SE, Lake RA. Long-term exposure of mesothelial cells to SV40 and asbestos leads to malignant transformation and chemotherapy resistance. *Carcinogenesis*, 2014 Feb 35 (2): 407-14.
184. Nelson D, Fisher S and Robinson BWS. The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment. *Journal of Immunology Research*, 2014 May e789069. (Review).
185. Creaney J, Dick IM, Meniawy TM, Leong S, Leon JS, Demelker Y, Segal A, Musk AW, Lee, YCG, Skates SJ, Nowak AK and Robinson BWS. Comparison of fibulin-3 and mesothelioma as markers in malignant mesothelioma. *Thorax*, 2014 Oct 69 (10): 895-902.
186. Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA. Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. *PLOS One* 2014 Aug 9 (8) e103125.
187. Fisher SA, Cleaver A, Lakiani DD, Khong A, Connor T, Wylie B, Lesterhuis WJ, Robinson BW, Lake RA. Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. *Journal of Translational Medicine*. 2014, Sep 12: 245, pp 1-9.
188. Anyaegbu CC, Lake RA, Heel K, Robinson BW, Fisher SA. Chemotherapy enhances cross-presentation of nuclear tumour antigens. *PLOS ONE* 2014, Sep, 9 (9) e107894.
189. Robinson C, Alfonso H, Woo S, Olsen N, Musk AW, Robinson BWS, Nowak AK, Lake RA. Effect of NSAIDs and COX-2 inhibitors on the incident and severity of asbestos-induced malignant mesothelioma: evidence from an animal model and a human cohort. *Lung Cancer*. 2014 1 October 86 (1):29-34.
190. Creaney J, Segal A, Olsen N, Dick IM, Musk AW, Skates SJ, Robinson BW. Pleural fluid mesothelin as an adjunct to the diagnosis of pleural malignant mesothelioma. *Disease Markers* 2014 Nov e413946
191. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ and Robinson BWS. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. *European Journal of Immunology*. 2015 Jan;45(1):49-59.

192. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ and Robinson BWS. Restoration of defective cross-presentation in tumours by gemcitabine. *Oncolimmunology*. 2015 4 (5).
193. Creaney J, Dick IM, Robinson BWS. Discovery of new biomarkers for malignant mesothelioma. *Current Pulmonology Reports*. 2015, 4 (1) pp 15-21. (Review).
194. Creaney J, Ma S, Sneddon S, Tourigny M, Dick IM, Leon J, Khong A, Fisher SA, Lake RA, Lesterhuis WJ, Nowak AK, Leary S, Watson M, Robinson BWS. Strong spontaneous tumour neo-antigen responses to tumors induced by a natural human carcinogen. *Oncolimmunology*. 2015 May 4:7 e1011492-1.
195. Leong SL, Zainudin R, Kazan-Allen L, Robinson BW. Asbestos In Asia. *Respirology*. 2015 May 20 (4): 548-555.
196. Leong SL, Lee YCG, Robinson BWS, Creaney JC. Role of mesothelin management in patients with cytology-negative pleural effusion undergoing medical thoracoscopy. *Pleura*, 2015 April 21, pp 1-7.
197. Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJN, Moses EK, Melton PE, de Klerk N, Musk AW, Robinson BWS, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma. *Gene* 2015 25 May 563 (1): 103-105.
198. Lesterhuis WJ, Rinaldi C, Jones A, Rozali EN, Dick IM, Khong A, Boon L, Robinson BW, Nowak AK, Bosco A, Lake RA. Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. *Scientific Reports* 2015 5, art. No. 12298.
199. Creaney J, Dick IM, Robinson BW. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. (Review). 2015. *Current Opinion in Pulmonary Medicine*. July 21 (4), 352-356.
200. Steer HJ, Robinson BWS. Axillary crackles are more prevalent than basal crackle in asbestos exposed workers with asbestosis. *Jacobs Journal of Pulmonology* 2015 1 (1) 04.
201. Robinson C, Dick IM, Wise MJ, Holloway A, Diyagama D, Robinson BWS, Creaney J, Lake RA. Consistent gene expression profiles in MexTag transgenic mouse and wild type mouse asbestos-induced mesothelioma. *BMC Cancer*. 2015 Dec 18, 15 (1) article no. 983.
202. Nowak AK, Cook AM, McDonnell AM, Millward MJ, Creaney J, Francis RJ, Hasani A, Segal A, Musk AW, Turlach BA, McCoy MJ, Robinson BW, Lake RA. A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. 2015. *Annals of Oncology* Dec 26 (12) 2483-90.
203. Morre, DJ, Hostetler B; Taggart DJ; Morre DM, Musk AW, Robinson BWS; Creaney J. ENOX2-based early detection (ONCOblot) of asbestos-induced malignant mesothelioma four to ten years in advance of clinical symptoms. *Clinical Proteomics*. 2016. Jan 13 (1) , art. no. 9103.
204. Creaney J, Dick IM, Musk AW, Olsen NJ, Robinson BWS. Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers. 2016. *Biomarkers*. 2016 Sep; 21(6):551-61.
205. Steven A, Fisher SA, Robinson BW. Immunotherapy for lung cancer. *Respirology*. 2016. Apr 21. (Invited Review).
206. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. *European Respiratory Review*. 2016. 25 (140) DOI 10.1183/16000617.0019-2016 1 June pp 189-98.
207. Greening DW, Hong J, Chen M, Robinson BWS, Dick IM, Creaney J, Simpson RJ. Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo. *Scientific Reports* 2016 Sep 8;6:32643. doi: 10.1038/srep32643.
208. Fisher SA, Aston WJ, Chee J, Khong A, Cleaver AL, Solin JN, Ma S, Lesterhuis WJ, Dick IM, Holt RA, Creaney J, Boon L, Robinson BW, Lake RA. Transient Treg depletion enhances therapeutic anti-cancer vaccine. *Immunity Inflammation and Disease* 2016 Nov 21; 5 (1):16-28. doi: 10.1002/iid3.136. eCollection 2017 Mar.
209. Creaney J, Dick IM, Leon JS, Robinson BWS. A proteomic analysis of the malignant mesothelioma secretome using iTRAQ. *Cancer Genomics & Proteomics*. 2017 14 (2) 103-17.
210. Chee J, Robinson BWS, Holt RA, Creaney J. Immunotherapy for lung malignancies from gene sequencing to novel therapies. 2017 *Chest*. 151 (4), 891-7.
211. Sneddon S, Patch A-M, Dick IM, Kazakoff S, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. *BMC Cancer* 2017 17: 396 DOI 10.1186/s12885-017-3382-6

212. Johnen G, Gawrych K, Raiko I, Casjens S, Pesch B, Weber DG, Taeger D, Lehnert M, Kollmeier J, Bauer T, Musk AW, Robinson BWS, Brüning T, Creaney J. Calretinin as a blood-based biomarker for mesothelioma. *BMC Cancer* 2017 17: 386.
213. McDonnell AM, Cook A, Robinson BWS, Lake RA, Nowak AK. Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters. *BMC Cancer* 2017 17: 417.
214. Creaney J and Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening and treatment. *Chest* 2017 July 152 (1) 143-149.
215. Aston WJ, Hope DE, Nowak AK, Robinson BWS, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. *BMC Cancer* 2017 17 (1) 16 October art. 684.
216. Patch AM, Nones K, Kazakoff SH, Newell F, Wood S, Leonard C, Holmes O, Xu Q, Addala V, Creaney J, Robinson BW, Fu S, Geng C, Li T, Zhang W, Liang X, Rao J, Wang J, Tian M, Zhao Y, Teng F, Gou H, Yang B, Jiang H, Mu F, Pearson JV, Waddell N. Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. *PLoS One*. 2018 Jan 10;13(1):e0190264
217. Sneddon S, Dick IM, Lee YCG, Musk AW, Patch A-M, Pearson J, Waddell N, Allcock RJN, Holt RA, Robinson BW, Creaney J. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. *Lung Cancer* 2018 Vol 119 May pp 64-70.
218. Marini KD, Croucher DR, McCloy RA, Gonzalez-Rajal A, Hastings JF, Chin V, Kostyrko K, Jayasekara S, Alamgeer M, Boolell V, Vaghiani V, Szczepny A, Han JZR, Waugh T, Lee HC, Oakes SR, Kumar B, Harrison CA, Hedger MP, Lorensuhewa N, Kita B, Barrow R, Robinson BW, de Kretser DM, Wu J, Ganju V, Sweet-Cordero EA, Burgess A, Martelotto LG, Rossello FJ, Cain JE, Watkins DN. Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. *Science Translational Medicine* 2018 25 July, Vol 10 Issue 451 Article eaat3504.
219. Fear VS, Tilsed C, Chee J, Forbes CA, Casey T, Solin JN, Lansley SM, Joost Lesterhuis W, Dick IM, Nowak AK, Robinson BW, Lake RA, Fisher SA. Combination immune checkpoint blockade as an effective therapy for mesothelioma. *Oncoimmunology*. 2018 Jul 30;7(10):e1494111.
220. Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R. Scientific Advances and New Frontiers in Mesothelioma Therapeutics. *J Thorac Oncol*. 2018 Sep;13(9):1269-128
221. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. *J Thorac Oncol*. 2018 Nov;13(11):1655-166
222. Hmeljak J, Sanchez-Vega F, Hoadley K...Robinson BWS, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. *Cancer Discovery* 2018 December Vol 8 Issue 12, pp. 1549-1565.
223. Chee J, Watson MW, Chopra A, Nguyen B, Cook AM, Creaney J, Lesterhuis WJ, Robinson BW, Lee YCG, Nowak AK, Lake RA, McDonnell AM. BMC Research Notes 2018 Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. 11: 864 doi: 10.1186/s13104-018-3953-x.
224. Abayasiriwardana KS, Wood MK, Prêle CM, Birnie KA, Robinson BW, Laurent GJ, McAnulty RJ, Mutsaers SE. Inhibition of collagen production delays malignant mesothelioma tumour growth in a murine model. *Biochemical and Biophysical Research Communications* 2019 510: 2, 5 March pp. 198-204.
225. Ye L, Ma S, Robinson BW, Creaney J. Immunotherapy strategies for mesothelioma - the role of tumour specific neoantigens in a new era of precision medicine. *Expert Review of Respiratory Medicine* 2019 13:2 181-192.

## 6.5 Published Abstracts

1. Robinson BWS, Musk AW. Benign asbestos pleural effusion. *Aust NZ J Med* 1981; 11: 340-341.
2. Robinson BWS, Pinkston P, Crystal RG. Natural killer cells in the normal human lung are impotent due to local suppression but can be activated with interleukin-2. *Clin Res* 1984; 32: 356.
3. Robinson BWS, Crystal RG. NK cells are present but inactive in the normal human lung. *Am Rev Respir Dis* 1984; 129: 7.
4. Robinson BWS, Crystal RG. Chrysotile asbestos directly suppresses the activity of natural killer cells. *Am Rev Respir Dis* 1984; 129: 7.
5. Robinson BWS, Crystal RG. Spontaneous production of gamma interferon by lung immune cells in pulmonary sarcoidosis. *Aust NZ J Med* 1985; 15: 491.
6. Robinson BWS, Pinkston P, Crystal RG. The human lung exhibits low levels of natural killer cell defence activity. *Aust NZ J Med* 1985; 15: 499.
7. Rom W, Robinson BWS, McLemore TL, Rose AH, Crystal RG. Lung mononuclear cells from individuals with chronic inorganic dust exposure spontaneously release immune interferon. *Am Rev Respir Dis* 1985; 131: 189.
8. Holt P, Robinson BWS, Kees U, Rose A. Extraction of human lung interstitial cells using a slicing/enzyme digestion method. *Aust NZ J Med* 1986; 16: 632.
9. Robinson BWS, Rose AH, Musk AW. Lung cells from some patients with chronic non-granulomatous interstitial lung diseases spontaneously release gamma interferon. *Aust NZ J Med* 1986; 16: 633.
10. Robinson BWS, Rose A, Hey A, Whittaker D, Musk AW. The alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite and chrysotile-exposed individuals. *Aust NZ J Med* 1986; 16: 634.
11. Hey A, Robinson BWS, Musk AW. Neutrophil chemotactic factor is spontaneously released by alveolar macrophages in patients with asbestosis. *Aust NZ J Med* 1986; 16: 628.
12. Robinson BWS, Morstyn G. Interleukin-2-activated natural killer cells are active against lung cancer cells. *Aust NZ J Med* 1986; 16: 621.
13. Holt P, Kees U, Wharton A, Robinson BWS The human lung interstitium has a different cell profile to blood and alveolus. *Am Rev Respir Dis* 1986; 133: 145.
14. Hayes A, Robinson BWS, Musk AW. Neutrophil chemotactic factor is spontaneously released by alveolar macrophages in patients with asbestosis. *Am Rev Respir Dis* 1986; 133: 198.
15. Musk AW, Robinson BWS, Rose AH, Hey A, Whitaker D. The alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite and chrysotile-exposed individuals. *Am Rev Respir Dis* 1986; 133: 199.
16. Robinson BWS, Morstyn G. Human lung cancer cells can be destroyed by interleukin 2 (IL-2) activated blood and lung natural killer (NK) cells. *Am Rev Respir Dis* 1986; 133: 286.
17. Robinson BWS, Rose AH, Musk AW. Gamma interferon is a mediator of non-granulomatous interstitial lung diseases. *Am Rev Respir Dis* 1986; 133: 146.
18. James A, Rose A, Sterret G, Musk AW. Robinson BWS Accurate bronchoalveolar lavage (BAL) assessment of alveolitis requires separate processing of 'airway' and 'alveolar' samples. *Am Rev Respir Dis* 1986; 133: 327.
19. Manning L, Hanks K, Robinson BWS Generation of lymphokine-activated killer (LAK) cells for therapy of human malignancies: comparison of different culture sera. *Aust NZ J Med* 1987; 17: 513.
20. Manning L, Robinson BWS Human malignant cells are susceptible to lysis by interleukin-2-activated lymphokine-activated killer (LAK) cells. *Aust NZ J Med* 1987; 17: 515.
21. Venaille T, Robinson BWS Epithelium, inflammation and asthma: a model for the study of epithelial cell detachment from basement membrane (BM). *Aust NZ J Med* 1987; 17: 523.
22. Mendis AHW, Venaille T, Vincent G, Robinson BWS Biochemical mediators of epithelial cell damage. *Aust NZ J Med* 1987; 17: 523.
23. Blum GR, Venaille T, Mendis AHW, Robinson BWS Potential role of major basic protein (MBP) and other eosinophil-derived proteins in asthma. *Aust NZ J Med* 1987; 17: 514.
24. Flexman J, Manning L, Robinson BWS. Augmentation of lung natural killer (NK) cell activity by administration of recombinant interleukin-2 (IL-2): comparison of different routes of administration. *Aust NZ J Med* 1987; 17: 515.
25. Flexman J, Manning L, Robinson BWS Local therapy of pleural malignancy: evaluation of intrapleural interleukin-2 (IL-2) and/or lymphokine-activated killer (LAK) cell administration. *Aust NZ J Med* 1987; 17: 516.

26. Hayes A, Musk AW, Lovegrove FT, Rose A, Ryan G, . Robinson BWS Asbestos exposure and pulmonary gallium uptake. *Aust NZ J Med* 1987; 17: 518.
27. Rose AH, Whitaker D, Musk AW, Hayes A, Robinson BWS Evaluation of lung alveolar asbestos body (AB) load using bronchoalveolar lavage (BAL). *Aust NZ J Med* 1987; 17: 519.
28. Bowman R, Manning L, Robinson BWS Tumour necrosis factor (TNF) boosts lymphocyte-mediated lysis of cultured and fresh human cancer cells. *Aust NZ J Med* 1987; 17: 516.
29. Holt PG, Kees U, Schon-Hegrad M, Ford Y, Bilyck N and. Robinson BWS Functional studies on human T-cells from solid lung tissue. *Aust NZ J Med* 1987; 17: 513.
30. Prichard MG, Naglan F, Rose A, Robinson BWS Lymphocytic broncho- alveolitis in patients with chronic cough. *Aust NZ J Med* 1987; 17: 511.
31. Mendis AH, Venaille T, McAleer R, . Robinson BWS Pathogenic mechanisms underlying allergic bronchopulmonary fungal disease. *Aust NZ J Med* 1988; 18: A527.
32. Bowman R, Naplan, F, Rose A, Neates N, Musk AW, .Robinson BWS. Tumour necrosis factor in interstitial lung disease. *Aust NZ J Med* 1988; 18: A527.
33. Venaille T, Warton A, Phillips MJ, Robinson BWS , Thompson PJ. Asthma mediators and epithelial cell membrane integrity. *Aust NZ J Med* 1988; 18: A536.
34. Rose AH, Musk AW, Neates N, Naglan F, Hayes A. Robinson BWS Asbestos exposure: evaluation of fibrotic, inflammatory and immunological processes in diseased v non-diseased individuals. *Aust NZ J Med* 1988; 18: A545.
35. Neates N, Musk AW, Christiansen F, Hayes A, Robinson BWS. Immunological profiles in subjects with crocidolite-induced alveolitis. *Aust NZ J Med* 1988; 18: A545.
36. Manning LS, Bowman R, Darby S, Musk AW, .Robinson BWS Lymphokine- activated killer (LAK) cells generated from patients with malignant mesothelioma (MM) are less effective against cultured MM cells than LAK cells from control individuals. *Aust NZ J Med* 1988; 18: A553.
37. Whitehead PR, Manning LS, Musk AW, Robinson BWS A low molecular weight immunosuppressive factor is present in the pleural fluid of patients with malignant mesothelioma (MM). *Aust NZ J Med* 1988; 18: A553.
38. Rose AH, Musk AW, Neates N, Hayes A, Robinson BWS Evaluation of fibrotic, inflammatory and immunological processes in asbestos exposed individuals. *Am Rev Respir Dis* 1989; 4: A203.
39. Manning LS, Bowman RV, Musk AW, Robinson BWS Patients with malignant mesothelioma (MM) demonstrate depressed lymphokine-activated killer (LAK) cell activity: effects of indomethacin (Indo), and intrapleural administration of interleukin-2 (IL-2) and LAK cells. *Am Rev Respir Dis* 1989; 4: A213.
40. Bowman R, Manning L, Davis M, Robinson BWS Profiles of drug and cytokine sensitivity of mesothelioma cell lines. *Am Rev Respir Dis* 1989; 4: A219.
41. Robinson BWS, Venaille T, McAleer R, Mendis AH, Nicholson T. Pathogenic mechanisms underlying allergic bronchopulmonary aspergillosis (ABPA): evaluation of direct fungus-induced epithelial damage. *Am Rev Respir Dis* 1989; 4: A465.
42. Rose AH, Bowman R, Musk AW, Neates N, Hayes A, . Robinson BWS Evidence of alveolitis with gamma interferon (IFN $\gamma$ ) and tumour necrosis factor alpha (TNF $\alpha$ ) production in asbestos-exposed individuals who have normal chest x-rays. *Am Rev Respir Dis* 1989; 4: A554.
43. Bowman R, Manning L, Davis M, Musk AW, Robinson BWS. Susceptibility of cultured human mesothelioma cells to lysis by drugs and cytokines. *Proc Am Assoc Cancer Res* 1989; 30:611.
44. Rose A, Bowman R, Musk AW, Neates N, Hayes A, . Robinson BWS Alveolitis and cytokine production in asbestos-exposed individuals who have normal chest x-rays. *Aust NZ J Med* 1989; 19(5): 643.
45. Bowman R, Manning L, Davis M, . Robinson BWS. Sensitivity of malignant mesothelioma to drugs and cytokines. *Aust NZ J Med* 1989; 19(5): 651.
46. Bowman R, Manning L, Davis M, Musk AW, Robinson BWS. Susceptibility of cultured human mesothelioma cells to lysis by drugs and cytokines. *Proc Am Assoc Cancer Res* 1989: 30:611.
47. Manning LS, Garlepp MJ, Christmas TI, Davis MR, Robinson BWS In vitro effect(s) of interferons on human malignant mesothelioma cell susceptibility to cytotoxic cells and MHC expression. *Am Rev Respir Dis* 1990; 141(4):A100.
48. Christmas TI, Musk AW, . Robinson BWS Phase II Study of recombinant human alpha interferon therapy in malignant pleural mesothelioma. *Proc Am Assoc Cancer Res* 1990; 31:1678.
49. Garlepp MJ, Manning LS, Christmas T, Davis M, . Robinson BWS Constitutive and inducible HLA antigen expression in malignant mesothelioma. *Proc Am Assoc Cancer Res* 1990; 31:1528.

50. Garlepp MJ, Christmas TI, Manning LS, Davis MR,. Robinson BWS HLA antigen expression in human malignant mesothelioma (MM). Conference on Lung Cancer, Melbourne 1991. Lung Cancer 1991;7:167.
51. Robinson BWS, Bowman RV, Christmas TI, Manning LS, Musk AW. Clinical experience using immunotherapy (IL-2/LAK cells or interferon alpha-2a) in malignant mesothelioma. Conference on Lung Cancer, Melbourne 1991. Lung Cancer 1991;7:172
52. Robinson BWS, Davis M, Garlepp MJ, Marzo A, Whitaker D, Manning LS. Evaluation of mesothelioma immunogenicity. Conference on Lung Cancer, Melbourne 1991. Lung Cancer 1991;7:172
53. Davis M, Manning LS, Whitaker D, Mutsaers SE, Robinson BWS A murine model of mesothelioma. Conference on Lung Cancer, Melbourne 1991. Lung Cancer 1991;7:168
54. Garlepp MJ, Christmas TI, Manning LS, Mutsaers S, Dench J, Robinson BWS The role of platelet derived growth factor in the growth of human malignant mesothelioma (MM). Conference on Lung Cancer, Melbourne 1991. Lung Cancer 1991;7:167
55. Mavaddat N, Robinson BWS, Rose AH, Manning LS, Garlepp MJ. Gamma delta T-cell cytotoxicity towards malignant mesothelioma cell lines. Aust NZ J Med 1991;21:645
56. Robinson BWS Christmas TI, Garlepp MJ, Manning LS,. Platelet-derived growth factor (PDGF) as an autocrine growth factor for malignant mesothelioma. Aust NZ J Med 1991;21:672
57. Rose AH, Garlepp MJ, Bowman RV, Robinson BWS A clonal analysis of T cells from normal human bronchoalveolar lavage (BAL) compared with blood. Aust NZ J Med 1991;21:672
58. Fitzpatrick DR, Garlepp MJ, Mutsaers SE, Davis MR, Bielefeldt-Ohmann H, Robinson BWS Transforming growth factor - beta: autocrine and paracrine roles in malignant mesothelioma. Am Rev Respir Dis 1993;147:A231 .
59. Robinson BWS, Dench JE, Rose AH, Bielefeldt-Ohmann H. Monocytes and alveolar macrophages from patients with sarcoidosis express heat shock/stress proteins. Am Rev Respir Dis 1993;147:A789.
60. Dench JE, Bielefeldt-Ohmann H, Rose AH, Currie B,. Robinson BWS Serum reactivity to HSP-65 in sarcoidosis patients. Am Rev Respir Dis 1993;147:A789.
61. Upham JW, Robinson BWS, Holt PG. Alveolar macrophages and T-cell activation: differential regulation of activation, cytokine production and proliferation. Am J Resp Dis, 1994:A263.
62. Upham JW., Holt BJ., Yabuhara A., Thomas WR., O'Keefe P., Palmer L., LeSouef P., Sly PD., Robinson BWS., Holt PG. T cell reactivity to allergens in atopic & normal subjects: covert in-vitro responses unmasked by serum free medium. Am J Resp Crit Care Med, 1995:A214.
63. Fitzpatrick DR., Bielefeldt-Ohmann H., Himbeck RP., Jarnicki AG., Marzo AL., Robinson BWS Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF- $\beta$  antisense RNA transfectants in a mesothelioma model. Am J Resp Crit Care Med, 1995:A671.
64. Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS, Robinson BWS A murine model of mesothelioma - pathology, immunology and biology. Am J Resp Crit Care Med, 1995:A571.
65. Davidson JA., Musk AW, Robinson BWS Intralesional cytokine therapy in cancer: a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. Am J Resp Crit Care Med, 1995:A848.
66. Leong CC, Marley JV, Garlepp MJ, Robinson BWS The generation of antitumour immune response to murine mesothelioma by the transfection of B7-1. Am J Resp Crit Care Med, 1995:A124
67. Venaille TV, Upham J, Robinson BWS Does asthmatic epithelium lack expression of 'normal' immunoregulatory genes? - evaluation of bronchial brushings using SQ-PCR. Am J Resp Crit Care Med, 1995:A776.
68. Jarnicki A, Fitzpatrick D, Himbeck R, Marzo A,. Robinson BWS, Bielefeldt-Ohmann H. Cytokine expression by tumour infiltrating lymphocytes during tumour growth-immunodeviation as a means of immuno-evasion? Am J Resp Crit Care Med, 1995:A36.
69. Mutsaers SE, Dawson JS, Versnel MA, Robinson BWS, Laurent GJ, McAnulty RJ. Increased procollagen production by mesothelioma cells compared with normal mesothelial cells and their response to TGF- $\beta$ . Am J Resp Crit Care Med, 1997;155(4):A762.
70. Marzo AL, Fitzpatrick, DR, Scott BM,. Robinson BWS Blockade of tumour-derived TGF- $\beta$  *in vivo* using antisense oligonucleotides. Am J Resp Crit Care Med, 1997;155(4):A462.
71. Robinson BWS, Mukherjee S, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi I, Scott B. Intratumoral cytokines generated by gene

- transfer or by infusion in solid tumours in humans and mice. *Am J Resp Crit Care Med*, 1997;155(4)A462.
72. Mukherjee S, Nelson D, Leong C, Marley J, Garlepp M, Robinson BWS. Vaccination with tumor cytokine transfectants delays growth but does not produce tumor eradication in a murine model of advanced malignancy. *American Journal of Resp Critical Care Med* 1999.
  73. Marzo AL, Lake RA, Callow M, Lo D, Sherman L, Robinson BWS, Scott B. Tumor antigens are constitutively presented in the draining lymph nodes. *American Journal of Resp Critical Care Med* 1999.
  74. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hael G, Buck M, de Klerk NH, Robinson BWS. Cisplatin and gemcitabine treatment for malignant mesothelioma (MM): a phase II study. *American Journal of Resp Critical Care Med* 1999.
  75. Robinson BWS, Mukherjee S, Jackaman C, Lake R, Ramshaw I, Haenel T, Smith D, Musk A, Morey S, van Hagen D, Himbeck R, Scott B, Harnett G, Stumbles P, Davidson J, van Bruggen I, Nelson D. Pox vectors for tumour immunotherapy - studies in mice and humans. *J of Gene Med*. 2001.
  76. Robinson BW, Mesothelioma biomarkers: what do we know and how do we use them? *Journal of Thoracic Oncology Vol 4 Issue 9*, pp S207-S208, Sep 2009.
  77. Creaney J, Segal A Robinson BW. Changes in mesothelin levels reflect response to chemotherapy in mesothelioma patients. *Journal of Thoracic Oncology Vol 4, Issue 9*, pp S345-S346, Sep 2009.
  78. Mukherjee S, Cadby G Robinson BW et al. A genome wide association scan for malignant mesothelioma. *Journal of Thoracic Oncology, Vol 6 Issue 3* pS16 Mar 2011.
  79. Creaney J, Segal A. Robinson BW. Mesothelioma biomarkers - now and the future. *Journal of Thoracic Oncology, Vol 6 Issue 3* pS4 Mar 2011.
  80. Mohamad FA, Cleaver A, Robinson BW. The effects of partial debulking surgery on tumor growth, survival and tumor specific immune responses. *Respirology, Vol 16 SI 1, Supp 2*, p 172, Nov 2011.
  81. Steer HJ, Cleaver A, Nowak A, Robinson BW, Lake RA Chemo-immunotherapy of mesothelioma: depletion of established, suppressive CD4 T cells is critical to achieving cures in a murine model. Winter Meeting of the British Thoracic Society Dec 7-9. *Thorax, Vol 66 Supp 4*, p A29, Dec 2011.
  82. Badrian B, Birnie KA Robinson BW et al. Mesothelioma specific microRNAs as novel biomarkers and regulators of tumor biology. *Respirology, Vol 17 SI Supp 1* p. 55, Apr 2012.
  83. Kirschner MB, Cheng YY Robinson BW et al. Assessment of circulating mirnas as potential biomarkers for malignant pleural mesothelioma (MPM). 3rd European Lung Cancer Conference (ELCC), Geneva, Switzerland. Apr 18-21 2012. *Journal of Thoracic Oncology, Vol 7, Issue 6* S83, June 2012.
  84. Kirschner MB, Cheng YY, Badrian B Robinson BW et al Circulating MIR-625-3P: a potential biomarker for malignant pleural mesothelioma *Journal of Thoracic Oncology Vol 7 Issue 9 Supp 3* p. S174, Sep 2012.

## 6.6 Abstracts Published in Meeting Proceedings Only

1. Robinson BWS, Crystal RG. Production of gamma interferon by human lung immune cells. Australian Society for Immunology, 14th Annual Meeting, 1984.
2. Robinson BWS, Pinkston P, Crystal RG. Natural killer cells are inactive in the normal human lung but can be activated with interleukin-2. Australian Society for Immunology, 14th Annual Meeting, 1984.
3. Robinson BWS. The activity of human NK cells is directly suppressed by asbestos. Australian Society for Immunology, 14th Annual Meeting, 1984.
4. Robinson BWS, Morstyn G. Human natural killer (NK) cells can be activated by recombinant interleukin-2 (IL-2) to destroy lung cancer cell targets. First Combined Meeting Australian Society for Immunology/New Zealand Society for Immunology 1985.
5. Robinson BWS, Morstyn GW. Human lung cancer cells can be destroyed by interleukin 2-activated blood and lung natural killer cells. Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1985.
6. Robinson BWS. NK activity against lung cancer cells. Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.
7. Robinson BWS. Human lung interstitial cells. Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.

8. Robinson BWS. Bronchoalveolar lavage studies of cell subpopulations and lymphokine production in different lung diseases. Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.
9. Hayes A, Robinson BWS. Neutrophil chemotaxis in asbestosis. Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.
10. Robinson BWS, Rose AH, Hayes A, James A, Musk AW. An active neutrophil alveolitis underlies pulmonary asbestosis. Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1986.
11. Robinson BWS, Venaille T. Development of an epithelial cell-basalt membrane model for evaluation of epithelial cell detachment in asthma. Asthma Foundation of Western Australia Annual Scientific Meeting, 1986.
12. Robinson BWS, Rose AH, Musk AW. Lung cells from some patients with chronic non-granulomatous interstitial lung diseases spontaneously release gamma interferon. 6th International Congress of Immunology, Toronto, 1986. Bowman R, Manning L, Robinson BWS. The effects of recombinant human TNF on lymphocyte-mediated lysis of cultured and fresh human cancer cells. Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1987.
13. Robinson BWS, Venaille T, Mendis AH, Vincent G, Blum R. Inflammation and epithelial cell damage in asthma. Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1987.
14. Whitehead P, Robinson BWS. Oncogenes in lung cancers. Thoracic Society of Australia Cell Biology Symposium, 1987.
15. Robinson BWS. The role of inflammatory cell-mediated epithelial cell damage in asthma. Thoracic Society of Australia Cell Biology Symposium, 1987.
16. Venaille T, Mendis AH, Robinson BWS. Evaluation of neutrophil and eosinophil-mediated epithelial cells. Asthma Foundation of Western Australia Annual Scientific Meeting, 1987.
17. Manning L, Robinson BWS. Human malignant mesothelioma cells are susceptible to lysis by interleukin-2-activated lymphokine-activated killer (LAK) cells. Cancer Research Association of WA Inaugural Scientific Symposium, 1987.
18. Flexman J, Manning L, Robinson BWS. Augmentation of lung natural killer (NK) cell activity by administration of recombinant interleukin-2 (IL-2): Comparison of different routes of administration. Cancer Research Association of WA Inaugural Scientific Symposium, 1987.
19. Bowman R, Manning L, Robinson BWS. Tumour necrosis factor (TNF) boosts lymphocyte-mediated lysis of cultured and fresh human cancer cells. Cancer Research Association of WA Inaugural Scientific Symposium, 1987.
20. Manning LS, Musk A, Robinson BWS. Patients with malignant mesothelioma (MM) demonstrate depressed lymphokine-activated killer (LAK) cell activity: effect of indomethacin (INDO). Australian Society for Immunology Annual Meeting 1988.
21. Manning L, Bowman R, Darby S, Robinson BWS. Preclinical investigation of the susceptibility of malignant mesothelioma (MM) to lymphokine-activated killer (LAK) cell cytolysis. Australian Society for Immunology Annual Meeting 1988.
22. Bowman R, Manning L, Robinson BWS. Effects of recombinant human tumour necrosis factor (TNF) on lymphocyte mediated lysis of mesothelioma cells. Australian Society for Immunology Annual Meeting 1988.
23. Rose AH, Bowman R, Musk AW, Robinson BWS. Gamma interferon (IFN  $\gamma$ ) and tumour necrosis factor (TNF) release in individuals exposed to asbestos. Australian Society for Immunology Annual Meeting 1988.
24. Robinson BWS, Mendis A, Venaille T. Inflammatory cell-mediated epithelial cell damage in asthma. Australian Society for Immunology Annual Scientific Meeting, Brisbane 1988.
25. Mendis AH, Venaille T, Robinson BWS. Proteases mediating epithelial cell damage. Asthma Foundation of Western Australia Annual Scientific Meeting, 1988.
26. Robinson BWS, Venaille T, McAleer R, Mendis AH, Nicholson T. Proteases in allergic diseases: evidence of direct allergen-mediated tissue damage. Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.
27. Manning LS, Davis MR, Robinson BWS. Asbestos exposure significantly inhibits lymphokine-activated killer cell (LAK) function in vitro. Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.



28. Robinson BWS, Bowman R, Musk AW, Neates N, Hayes A. Evaluation of T-cell and macrophage cytokine release as early markers of human lung disease. Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.
29. Garlepp MJ, Manning LS, Christmas TI, Davis MR, Robinson BWS. Heterogeneity of constitutive and inducible MHC antigen expression in malignant mesothelioma. Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.
30. Bowman RV, Davis MR, Manning LS, Robinson BWS. In vitro assessment of the susceptibility of cultured human malignant mesothelioma cells to the direct anti-proliferative effects of recombinant human cytokines and chemotherapeutic drugs. Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.
31. Robinson BWS, Venaille T, Mendis AH, McAleer R. Aspergillus-derived proteases and epithelial cell damage. Asthma Foundation of Western Australia Annual Scientific Meeting, 1989.
32. Robinson BWS, Rose AH, Bowman R. Cytokine release as an early marker of pulmonary asbestosis. Proceedings 7th International Congress of Immunology, Berlin, 1989.
33. Manning LS, Davis M, Robinson BWS. Asbestos fibres suppress lymphokine-activated killer cell generation. Proceedings 7th International Congress of Immunology, Berlin, 1989.
34. Manning LS, Davis MR, Robinson BWS. Asbestos significantly inhibits lymphokine-activated killer (LAK) cell function in vitro. Cancer Research Association of WA Symposium 1989.
35. Bowman RV, Manning LS, Davis MR, Musk AW, Robinson BWS. Susceptibility of cultured human malignant mesothelioma cells to cytotoxic drugs, cytokines and immune effector cells: in vitro assessment. Cancer Research Association of WA Symposium 1989.
36. Manning LS, Christmas TI, Robinson BWS. Efficacy of interferon alpha in the treatment of malignant mesothelioma. Combined Biological Sciences Scientific Meeting, 1990.
37. Garlepp MJ, Rose AH, Robinson BWS, Manning LS. Susceptibility of mesothelioma cells to lysis by a TcR-d1 positive T-cell clone. Proceedings of the American Association for Cancer Research Special Conference on the Molecular Basis of tumour immunology, Virginia 1990.
38. Manning LS, Christmas TI, Robinson BWS. Efficacy of interferon alpha (IFNa) in the treatment of malignant mesothelioma. Proceedings of the International Conference on Biological Treatment of Melanoma and Other Cancer, Newcastle 1990.
39. Mavaddat N, Rose AH, Manning LS, Robinson BWS, Garlepp MJ. Gamma delta T-cell cytotoxicity toward malignant mesothelioma cell lines. Australian Society for Immunology Annual Scientific Meeting, Melbourne December 1990.
40. Rose AH, Garlepp MJ, Bowman RV, Robinson BWS. Characterisation of T-cell clones from bronchoalveolar lavage from normal humans: comparison with blood. Proceedings of the Australian Society for Immunology Annual Scientific Meeting, Melbourne December 1990.
41. Rose AH, Garlepp MJ, Robinson BWS. Clonal analysis of CD4+ T lymphocytes in sarcoidosis. Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p52
42. Manning LS, Davis M, Garlepp MJ, Marzo A, Whitaker D, Robinson BWS. Evaluation of immunogenicity of mouse mesothelioma cells by immunization. Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p77.
43. Richardson DR, Turner KJ, Robinson B. The mechanism(s) of IgE uptake by human macrophages and A B-lymphoblastoid cell line (WIL-2WT): A preliminary report. Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p66.
44. Dench JE, Rose AH, Robinson BWS, Bielefeldt-Ohmann H. Mononuclear phagocytic cells from patients with sarcoidosis express heat shock proteins. Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p57.
45. Dench JE, Bielefeldt-Ohmann H, Rose AH, Currie B, Robinson BWS. Patients with sarcoidosis express reactivity to a 65-kilodalton heat shock protein. Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p58
46. Rose AH, Dench JE, Garlepp MJ, Robinson BWS. Clonal analysis of bronchoalveolar lavage (BAL) T-cells in interstitial lung disease (ILD). Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p64
47. Bielefeldt-Ohmann H, Marzo A, Davis M, Fitzpatrick DR, Robinson BWS. In situ phenotyping of mononuclear cell infiltrates in experimental malignant mesothelioma: a marker of host responses? Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p84

48. Fitzpatrick DR, Garlepp MJ, Mutsaers SE, David MR, Bielefeldt-Ohmann H, Robinson BWS. Transforming growth factor-beta: autocrine and paracrine roles in malignant mesothelioma. Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p85
49. Upham JW, Bilyk N, Robinson B, Holt P. Does nitric oxide mediate the immunosuppressive activity of alveolar macrophages? Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 028.
50. Fitzpatrick DR, Garlepp MJ, Mutsaers SE, Davis MR, Bielefeldt-Ohmann, Robinson BWS. Transforming growth factor - Beta: autocrine and paracrine roles in malignant mesothelioma? Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 026.
51. Robinson BWS, Leong CC, Garlepp MJ. Inoculation of allogeneic MHC transfectants does not confer immunity to the parental mesothelioma cell line. Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 027.
52. Dench A, Rose A, Bielefeldt-Ohmann H, Robinson B. A potential role for stress proteins in the pathogenesis of sarcoidosis. Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, P92.
53. Jarnicki A, Fitzpatrick D, Marzo A, Robinson B, Bielefeldt-Ohmann H. cytokine production and surface antigen profile of tumour infiltrating leukocytes (TIL) in malignant mesothelioma. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P41.
54. Peroni D, Fitzpatrick D, Robinson B. Inhibition of platelet-derived growth factor-A (PDGF-A) expression in malignant mesothelioma by antisense mRNA production. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P75.
55. Fitzpatrick D, Bielefeldt-Ohmann H, Robinson B. Analysis of the roles of transforming growth factor-beta in the tumorigenesis of malignant mesothelioma. Proceedings of Clinical Oncological Society of Australia, Perth 1993, 76.
56. Leong CC, Robinson B, Garlepp M. The generation of an antitumour immune response by allogeneic MHC gene transfer. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P78.
57. Jarnicki A, Fitzpatrick D, Marzo A, Robinson B, Bielefeldt-Ohmann H. Cytokine production and surface antigen profile of tumour infiltrating leukocytes (TIL) in malignant mesothelioma. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P119.
58. Upham J, Robinson B, Holt P., Alveolar macrophages and T cell activation:- differential regulation of activation, cytokine production and proliferation. Proceedings of American Thoracic Society, Boston 21-25 May 1994.
59. Wood-Baker R, Musk A, Morey S, Drury P, Robinson B. Intralesional interferon treatment of malignant mesothelioma. Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Hamilton Island 9-14 April 1994, P212.
60. Upham J, Robinson B, Holt P. Alveolar macrophages and T cell activation: differential regulation of activation markers, cytokine production and proliferation. Proceedings thoracic Society of Australia and New Zealand Annual Scientific Meeting, Hamilton Island 9-14 April 1994, P38.
61. Upham J, Robinson B, Holt P. The soluble form of the low affinity IgE receptor enhances allergen specific T cell proliferation. Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Hamilton Island 9-14 April 1994, P163.
62. Davidson JA., Musk AW., Robinson BWS. Ideas on staging progression, and new prognostic test for mesothelioma. European School of Lung Cancer, Medical Oncology Group meeting, Sydney, 1994.
63. Davidson JA., Musk AW., Robinson BWS. In vitro and in vivo effect of Taxol on mesothelioma murine and human cell lines and investigation of cremophor on mesotheliomas sensitivity to Adriamycin. Clinical Oncology Society of Australia, Adelaide, November 1994.
64. Davidson JA and Robinson BWS. To evaluate the effect of granulocyte macrophage colony stimulating factor (GM-CSF) and retinoids on mesothelioma growth and any additive effect for the combination with alpha interferon. Clinical Oncology Society of Australia, Adelaide, November 1994.
65. Marzo AL., Fitzpatrick DR., Robinson BWS. Inhibition of malignant mesothelioma (MM) growth by anti-sense oligonucleotides specific for transforming growth factor-beta (TGF- $\beta$ ). Australian Society of Immunology, Canberra 5-7 December, 1994.
66. Upham J, Holt B, Yabuhara A, Thomas W, O'Keefe P, Palmer L, LeSouef P, Sly P, Robinson B, Holt P. T-cell reactivity to allergens in atopic and normal subjects: covert in vitro responses unmasked by serum free medium. ATS International Conference, Seattle Washington, May 21-24, 1995.

67. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF- $\beta$  antisense RNA transfectants in a mesothelioma model. ATS International Conference, Seattle Washington, May 21-24, 1995.
68. Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS., Robinson BWS. A murine model of mesothelioma - pathology, immunology and biology. ATS International Conference, Seattle Washington, May 21-24, 1995.
69. Davidson JA, Musk AW, Robinson BWS. Intralesional cytokine therapy in cancer: a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. ATS International Conference, Seattle Washington, May 21-24, 1995.
70. Leong CC, Marley JV, Garlepp MJ, Robinson BWS. The generation of antitumour immune response to murine mesothelioma by the transfection of B7-1. ATS International Conference, Seattle Washington, May 21-24, 1995.
71. Venaille TV, Upham J., Robinson BWS. Does asthmatic epithelium lack expression of 'normal' immunoregulatory genes? - evaluation of bronchial brushings using SQ-PCR. ATS International Conference, Seattle Washington, May 21-24, 1995.
72. Jarnicki A., Fitzpatrick D, Himbeck R, Marzo A, Robinson BWS, Bielefeldt-Ohmann H. Cytokine expression by tumour infiltrating lymphocytes during tumour growth-immunodeviation as a means of immuno-evasion? ATS International Conference, Seattle Washington, May 21-24, 1995.
73. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF- $\beta$  antisense RNA transfectants in a mesothelioma model. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
74. Caminschi I, Jarnicki A, Fitzpatrick D, Marzo A, Himbeck R, Bundell C, Scott B, Robinson BWS, Bielefeldt-Ohmann H. Growth of a murine malignant mesothelioma cell line in vivo: lack of immune aggression due to immune deviation. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
75. Marley JV, Leong CC, Robinson BWS, Garlepp MJ. Co-expression of allogeneic MHC and a co-stimulatory molecule (B7-1) augments the immune response to a mesothelioma cell line. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
76. Leong CC, Marley JV, Robinson BWS, Garlepp MJ. B7-1 transfection can abrogate tumour non-immunogenicity but in vivo tumour growth occurs via a decay in CTL activity. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
77. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BWS. A murine model of mesothelioma - pathology, immunology and biology. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
78. Davidson JA, Musk AW, Robinson BWS. Intralesional cytokine therapy in cancer a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
79. Davidson JA, Robinson BWS. In vitro and in vivo effect of Taxol on mesothelioma murine and human cell lines and investigation of cremophor effect on mesothelioma's sensitivity to Adriamycin. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
80. Marzo AL, Fitzpatrick DR, Scott B, Bundell C, Robinson BWS. Antisense oligonucleotides specific for transforming growth factor-beta (TGF- $\beta$ ) inhibit the growth of malignant mesothelioma (MM) both in vitro and in vivo. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.
81. Marzo AL, Scott BM, Fitzpatrick D, Robinson BWS. Antisense oligonucleotides specific for TGF- $\beta$  inhibit the growth of malignant mesothelioma. ASI Meeting 1995, Gold Coast, Queensland, Australia, 3-7 December, 1995.
82. Caminschi I, Scott BM, Robinson BWS. Recombinant IL-12 administration prevents the growth of a murine malignant mesothelioma cell line in vivo. ASI Meeting 1995, Gold Coast, Queensland, Australia, 3-7 December, 1995.
83. Caminschi I, Scott B, Garlepp M, Robinson. Recombinant IL-12 prevents the growth of murine malignant mesothelioma. ASI Meeting, 1996, Adelaide, South Australia, Australia, 1-5 December, 1996.
84. Caminschi I, Venetsanakos E, Garlepp M, Robinson BWS, Scott B. Local secretion of interleukin-12 inhibits proximal and distal tumour growth. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

85. Robinson C, Callow M, Robinson BWS, Lake RA. Tumour antigens from malignant mesothelioma. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
86. Marzo AL, Himbeck R, Haenal T, Lake RA, Robinson BWS, Scott B. The presence of a strong tumour antigen and specific T cells does not induce an effective anti-tumour response. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
87. Marzo AL, Callow M, Robinson BWS, Lake RA, Scott B. The recognition of tumour antigens by effector T cells in vivo - a role for cross priming in lymphoid organs. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
88. Marzo AL, Fitzpatrick DR, Scott B, Robinson BWS. Blockade of tumour-derived TGF- $\beta$  using antisense oligonucleotides. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
89. Mukherjee S, Haenal T, Epton M, Lake RA, Harnett G, Phillips P, Drury P, Morey S, Smith D, Ramshaw I, Davidson J, Musk AW, Robinson BWS. Persistent vaccinia virus-interleukin 2 (VV-IL2) gene expression in malignant mesothelioma (MM) despite evidence of anti-viral immunity. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
90. Venetsanakos E, Caminschi I, Chan J, Scott B, Robinson BWS. Characterisation of resident and splenic macrophages in murine mesothelioma model. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.
91. McLaren BR, Robinson BWS, Lake RA. Mesothelioma: Chemotherapy, cytokines and resistance. NZ Society for Oncology Annual Scientific Congress, Christchurch, New Zealand, May 1998.
92. Lake RA, Robinson BWS, Hayball JD. MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.
93. Hayball JD, Marzo AL, Scott BM, Robinson BWS, Lake RA. Partial agonism of a polyclonal set of human V $\beta$ 17 expressing T cell by an altered bacterial superantigen. QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.
94. Marzo AL, Lake RA, Callow M, Robinson BWS, Scot B. Tumour antigens are presented constitutively to tumour-specific T cells in the draining lymph nodes. QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.
95. Hayball JD, Marzo AL, Scott BM, Robinson BWS, Lake RA. Partial agonism of a polyclonal set of human V $\beta$ 17 expressing T cell by an altered bacterial superantigen. Australian Society of Immunology, Melbourne, Australia, 1st-5th December, 1998.
96. Lake RA, Robinson BWS, Hayball JD. MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. Australian Society of Immunology, Melbourne, Australia, 1st-5th December, 1998.
97. Lake RA, Robinson BWS, Hayball JD. MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. 10th International Congress of Immunology, India, 1st-6th November, 1998.
98. Marzo AL, Lake RA, Callow M, Lo D, Sherman L, Robinson BWS, Scott BM. TCR Transgenic analysis of class I and II restricted tumour-specific T cell responses: CD8 response deficits occur distal to local antigen presentation. Proc of Am. Assoc. for Immunologists, ASM 1999.
99. Mukherjee S, Haenal T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson BWS. TCR transgenic analysis of class I and II restricted tumour-vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Proc of Am. Assoc. for Immunologists, ASM 1999.
100. Robinson BWS. Gene Therapy for Cancer. Proc of Australasian Pharmaceutical Science Assoc, APSA. Annual Conference 1999.
101. Jackaman C, Bundell C, Kinnear B, van Hagen D, Robinson BWS, Nelson D. Interleukin-2 intra-tumoral immunotherapy of malignant mesothelioma: Size does matter. 6th International Mesothelioma Interest Group Conference. Perth 2002.
102. Robinson BWS, Creaney J, Lake RA, Nowak A, Musk AW, de Klerk N, Winzell P, Scholler N, Hellstrom KE, Hellstrom I. Serum mesothelin is elevated in mesothelioma patients and can predate diagnosis. 6th International Mesothelioma Interest Group Conference. Perth 2002.
103. Nowak A, Robinson BWS, Lake RA. Gemcitabine and activating anti-CD40 antibody synergise to cure an established murine malignant mesothelioma (MM). 6th International Mesothelioma Interest Group Conference. Perth 2002.

104. Nowak A, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BWS. Quality of life analysis from a multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma (MM). 6th International Mesothelioma Interest Group Conference. Perth 2002.
105. Nelson D, Jackaman C, Bundell C, Robinson BWS. Evaluation of tumour-specific T cell responses during progression of mesothelioma. 6th International Mesothelioma Interest Group Conference. Perth 2002.
106. Van Bruggen I, Jackaman C, Caminschi I, Liu Y, Robinson BWS. Does constant rate cytokine infusion in mesothelioma offer a better delivery regimen than repeated bolus injections?. 6th International Mesothelioma Interest Group Conference. Perth 2002.
107. Smith A, van Bruggen I, Broomfield S, Himbeck R, Bundell C, Creaney J, Nelson D, Lake RA, Robinson BWS. Autologous mesothelioma cell lysate as a source of tumour antigens for dendritic cell pulsing. 6th International Mesothelioma Interest Group Conference. Perth 2002.
108. Broomfield S, van Bruggen I, Smith A, Robinson BWS. Enhancing the immune response to mesothelioma antigens with heat shock protein enriched autologous tumour lysate. 6th International Mesothelioma Interest Group Conference. Perth 2002.
109. Creaney J, Robinson BWS, Musk AW, de Klerk N, Lake RA. Identification of mesothelioma-specific antigens. 6th International Mesothelioma Interest Group Conference. Perth 2002.
110. Creaney J, Lake RA, Nowak A, Musk AW, Robinson BWS. Elevated levels of mesothelin-family proteins in malignant mesothelioma. 6th International Mesothelioma Interest Group Conference. Perth 2002.
111. Robinson BWS, Nowak A, Marzo A, Himbeck R, Stumbles P, Frelinger J, Heath W, Scott B, Lake R. Tumor antigen cross presentation and the impact of induction of tumor cell apoptosis in vivo on specific CD8 function and CD40 responses. Keystone International Conference, Colorado, USA 2003.
112. Robinson BWS, Nowak A, Marzo A, Himbeck R, Stumbles P, Frelinger J, Heath W, Scott B, Lake R. Tumor antigen cross presentation, tumor cell apoptosis - specific CD8 and CD40 responses. The Annual American Association of Immunology Meeting. Denver, Colorado, USA 2003.
113. Nelson DJ, Jackaman C, Robinson BWS, Zhan Y, Lew AM. Intra-tumoral activating anti-CD40 requires further 'help' offered by intra-tumoral interleukin-2 to induce reliable and permanent regression of large, rapidly growing solid tumors. The Annual American Association of Immunology Meeting. Denver, Colorado, USA 2003.
114. Nowak AK, Robinson BWS, Lake R. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumours. Medical Oncology Group, RACP Australia, Annual Scientific Meeting 2003.
115. Robinson BWS, Heath W, Nowak AJ, Frelinger J, Lake RA, Scott B, Stumbles P, Himbeck R, Marzo A. Tumor-Specific CD8 cells are constitutively 'cross-armed' but only in tumor-draining nodes and are driven out of lymph nodes by CD40 stimulation. 12th International Congress of Immunology, Montreal, July 2004.
116. Creaney J, Robinson BWS. Serum Mesothelin-Related Protein - a new serum marker for mesothelioma. International Mesothelioma Interest Group, Italy 2004.
117. Brown MD, Vivian JB, Currie AJ, Price P, Robinson BWS, Hall JC. Are Tumour Vaccines Logical? Urological Society of Australasia State Meeting (WA), Bunker Bay Western Australia November 5-7 2004.
118. Brown MD, Vivian JB, Currie AJ, Price P, Robinson BWS, Hall JC. Postoperative Tumour Neo-Antigen Presentation in Murine Models of Primary and Metastatic Malignancy. Australasian Society of Immunology National Convention, Adelaide South Australia, December 12-16 2005.
119. Brown MD, Currie AJ, Vivian JB, Robinson BWS. Postoperative Tumour Neo Antigen Presentation, Keystone Cancer Symposium, Keystone Colorado March 19-24 2005.
120. Brown MD, Vivian JB, Currie AJ, Robinson BWS. Surgery Re-Sets the Anti-Tumour Immune Response. Urological Society of Australasia State Meeting (WA), Bunker Bay Western Australia, November 4-6 2005.
121. Sherwood A, Creaney J, Robinson BWS, Lake R. Identification of Key Genetic Changes Involved in Mesothelial Cell Transformation. Combined Biological Sciences Meeting (CBSM), Perth Australia 2002.
122. Sherwood A, Creaney J, Lake R, Robinson BWS. Identification of Genetic Markers for Mesothelioma. The International Mesothelioma Interest Group(IMIG) meeting, Perth, Australia 2002.
123. Sherwood A, Robinson BWS, Nelson D, Lake R. Identification of Tumour Antigens Associated with Mesothelial Cell Transformation. Australasian Society of Immunology (ASI) meeting, Perth, Australia, 2003.
124. Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Identification of Key Genetic Markers Associated with Mesothelial Cell Transformation. ComBio meeting, Perth, Australia 2004.

125. Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Characterisation and Gene Profiling of an In Vitro Model of Mesothelial Cell Transformation. 4th National Microarray Conference and Inaugural Meeting of the Australasian Microarray and Associated Technologies Assoc.(AMATA), Perth, Australia 2004.
126. Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Characterisation of an In Vitro Model of Mesothelial Cell Transformation. Keystone Symposia- Cancer and Development(J6), Banff, Alberta, Canada 2005.
127. Creaney J, Lake R, Musk AW, de Klerk N, Robinson BWS. Soluble Mesothelin Related Protein (SMRP): A marker for Mesothelioma. Molecular and Cell Biology of Cancer, Melbourne, November 14-16 2005.
128. Creaney J, Lake R, Robinson BWS. Ribonucleotide reductase: levels in malignant mesothelioma. Cancer Knowledge - Cancer practise: The fifth WA State Cancer Conference, Perth October 18, 2005.
129. Sherwood A, Robinson BWS. Profiling of an In Vitro Model of Mesothelial Cell Transformation. The fifth WA State Cancer Conference, Perth October 18, 2005.
130. Mutsaers S, Robinson BWS, Nelson D, Lake R. Keystone Symposia-Stem Cells, Senescence and Cancer(D5), Singapore 2005.
131. Robinson BWS, Creaney J. Mesothelioma- serum markers- potential value in diagnosis, monitoring and screening. The Thoracic Society of Australia and New Zealand, Perth March 20-23 2005.
132. Creaney J, Segal A, Musk AW, De Klerk NH & Robinson BWS. Potential biomarker for mesothelioma. 36<sup>th</sup> Annual Scientific and Business Meeting of the Australian Society of Cytology, November 2006, Perth Western Australia.
133. Robinson BWS, Creaney J, Segal A, Musk AW, De Klerk N, Skates SJ & Pass HI. Biomarkers for early detection of asbestos-induced cancer. Gordon Conference. January 2007.
134. Creaney J & Robinson BWS. Biomarkers in malignant mesothelioma. Thoracic Society of Australia and New Zealand, April 2007.
135. McDonnell, AM, Prosser, AC, Van Bruggen, I, Currie, AJ & Robinson BWS. Cross presentation of tumour antigens from tumour dendritic cells is blocked. TSANZ ASM 2008.
136. Creaney J, Boudville N, Musk AW, Segal A and Robinson BWS. Screening for mesothelioma using serum v urine mesothelin levels. TSANZ ASM 2008.
137. Robinson BWS, Currie AJ, Brown M, Lake R, Nowak A. Synergism between immunotherapy and conventional chemotherapy and surgery for lung malignancies. TSANZ ASM 2008.
138. Broomfield S, Van der Most R, Prosser A, Mahendran S, Robinson BWS, Currie A. Human and mouse tumors express TLR7: evidence for in-vivo sensitivity to local treatment with Imiquimod. TSANZ ASM 2008.
139. McDonnell AM, Prosser AC, Van Bruggen I, Currie AJ, Robinson BWS. Cross presentation of tumour antigens from tumour dendritic cells is blocked. ATS ASM 2008.
140. Creaney J, Boudville N, Musk AW, Segal A, Robinson BWS. Screening for mesothelioma using serum v urine mesothelin levels. ATS ASM 2008.
141. Robinson BWS, Currie AJ, Brown M, Lake R, Nowak A. Synergism between immunotherapy and conventional chemotherapy and surgery for lung malignancies. ATS ASM 2008.
142. Broomfield S, Prosser A, Van der Most R, Mahendran S, Robinson BWS, Currie AJ. [Locally administered toll-like receptor 7 agonists drive systemic anti-tumour immune responses that are enhanced by anti-CD40 immunotherapy. Australian Society for Medical Research - Medical Research Week Symposium 2008. Curtin University, Bentley, Western Australia. \(Oral presentation\).](#)
143. [Broomfield S, Prosser A, Van der Most R, Mahendran S, Robinson BWS, Currie AJ. A locally administered toll-like receptor-7 agonist drives systemic anti-tumour immune responses that are enhanced by anti-CD40 immunotherapy. Toll 2008 Conference, Lisbon, Portugal. \(Poster presentation\).](#)
144. Creaney J, Segal A, Nowak AK, Francis RJ, Alvarez J, Musk AW, Robinson BWS. The use of mesothelin for monitoring patients with mesothelioma. International Mesothelioma Interest Group Meeting. Amsterdam 2008. (Oral presentation).
145. Robinson C, Alfonso H, Woo S, Nowak AK, Robinson BWS, Musk AW, Lake RA. Statins do not alter the incidence of mesothelioma in asbestos exposed mice or humans. International Mesothelioma Interest Group meeting, Cape Town 2014.
146. McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, Robinson BWS. Mesothelioma-infiltrating dendritic cells exhibit defective cross-presentation of tumour antigens which is reversed by gemcitabine. International Mesothelioma Interest Group meeting, Cape Town 2014.

147. Lesterhuis WJ, Salmons J, Aston W, Nowak AK, Khong A, Dick IM, Robinson BWS, Lake RA. Gemcitabine synergistically increases treatment efficacy of CTLA-4 blockade in murine mesothelioma. International Mesothelioma Interest Group meeting, Cape Town 2014.
148. Lesterhuis WJ, Rinaldi C, Jones A, Khong A, Dick I, Nowak AK, Robinson BWS, Bosco A, Lake RA. A systems biology approach identifies synergistic drug-immunotherapy combinations. International Mesothelioma Interest Group meeting, Cape Town 2014. (Oral presentation).
149. Khong A, Rozali EN, Salmons J, Nowak AK, Robinson BWS, Lesterhuis WJ, Lake RA. Dual checkpoint blockade using anti-PD-1 and anti-CTLA4 combined with cisplatin chemotherapy is effective in a murine mesothelioma model. International Mesothelioma Interest Group meeting, Cape Town 2014. Poster presentation.
150. Robinson C, Alfonso H, Woo S, Nowak AK, Robinson BWS, Musk AW, Lake RA. Aspirin does not affect asbestos-induced mesothelioma in MexTAG mice consistent with data from a human cohort. International Mesothelioma Interest Group meeting, Cape Town 2014. Oral presentation.
151. Cook AM, McDonnell A, Lake RA, Francis R, Millward M, Robinson BWS, Nowak AK. A phase Ib clinical trial of the CD40 activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma. International Mesothelioma Interest Group meeting, Cape Town 2014 (Poster presentation).
152. Lesterhuis WJ, Rinaldi C, Jones A, Khong A, Nowak AK, Robinson BW, Bosco A, Lake RA. A systems biology approach to identify synergistic drug-checkpoint blockade combinations in cancer. 27<sup>th</sup> Lorne Cancer Conference, Lorne Vic. Australia, February 12-14, 2015. (oral presentation).
153. Lesterhuis WJ, Rinaldi C, Jones A, Khong A, Nowak AK, Robinson BW, Bosco A, Lake RA. A systems biology approach identifies synergistic drug-immunotherapy combinations. 5<sup>th</sup> Biennial Cancer Council Research Symposium, Perth WA, Australia, November 20, 2014. (oral presentation).
154. Lesterhuis WJ, Rinaldi C, Jones A, Khong A, Nowak AK, Robinson BW, Bosco A, Lake RA. A systems biology approach identifies synergistic drug-immunotherapy combinations. 2<sup>nd</sup> National Melanoma Conference, Perth WA, Australia, October 10-11, 2014. (oral presentation).
155. Creaney J, Sneddon S, Dick I, Cadby G, Brims F, Melton P, Moses E, Musk AW, Robinson B. Frequency of germline BAP1 mutations in Australian mesothelioma. 12<sup>th</sup> Annual Meeting of the Australasian Biospecimens Network Association. Christchurch. November 2014.

## 7. INVITED LECTURES AND INVITED CONTRIBUTIONS TO MAJOR MEETINGS

### 2018

#### National

##### Invited speaker

Eradicate Cancer Can advanced immunotherapy make it possible?, 15-17 March, Melbourne  
“The potential therapeutic role of personalised neoantigen cancer vaccines”

### 2017

#### International

##### Invited speaker

Augmenting and broadening T-cell responses against mutated tumor neo-antigens. 6 April 2017, Vanderbilt-Ingram Cancer Center (VICC) Nashville, Tennessee USA.

##### Invited speaker

BC Cancer Agency Research Seminar Series, 10 April 2017, Vancouver, Canada.

##### Keynote speaker

Cold Spring Harbor Asia, Suzhou Industrial Park Tumor Immunology - Immunotherapy 22-26 October, China.

##### Invited speaker

Chinese University of Hong Kong, Immunotherapy for Thoracic Malignancy, October 11, Hong Kong.

##### Invited speaker

Singapore Immunology Network, 9 & 10 October, Singapore.

##### Invited speaker

Chinese Society for Clinical Oncology (CSCO) 20<sup>th</sup> Annual Meeting, September 26-30

“Immunotherapy and the role of neoantigens”, Xiamen, China.

#### National

##### Invited speaker

Immunotherapy@Brisbane, May

“Augmenting and broadening T-cell responses against mutated tumour neo-antigens”, Brisbane.

### 2016

#### International

Member, Scientific Abstract Committee, Plenary Speaker, Plenary Chair, Session Chair

13<sup>th</sup> International Mesothelioma Interest Group (iMig) Conference, May, Birmingham, UK.

#### National

##### Guest speaker

Cancer Nurses Society, March, Perth.

##### Invited speaker

Thoracic Society of Australia and New Zealand (TSANZ) Annual Scientific Meeting, , April: “Strategies for improving immunotherapy for lung tumours - Identifying tumour antigens using gene sequencing”, Perth.

### 2015

#### International

##### Invited speaker

16<sup>th</sup> World Conference on Lung Cancer, September, Denver Colorado, USA.

Sanger Institute, September, Cambridge UK.

#### National

##### Plenary Chair

Australasian Society for Immunology (ASI) Annual Scientific Meeting, November, Canberra.

### 2014

#### International

##### Faculty Member and invited speaker

12<sup>th</sup> International Mesothelioma Interest Group (iMig) Conference, October, Cape Town, South Africa.

##### Invited speaker

19<sup>th</sup> Congress of Asian Pacific Society of Respirology (APSR), November, Bali, Indonesia.

#### National

##### Plenary session speaker



Suicide Prevention Australia (SPA) National Conference, July, Perth.

## 2013

### International

#### Invited Speaker

53<sup>rd</sup> annual meeting of the Japanese Respiratory Society, April, Tokyo, Japan.

University of Indonesia, Faculty of Medicine, May, Jakarta, Indonesia.

Persehabatan Hospital, May, Jakarta, Indonesia.

World Conference on Lung Cancer, October, Sydney.

## 2012

### International

#### Invited Speaker

PIPKRA, University of Indonesia, Faculty of Medicine, February, Jakarta, Indonesia.

American Thoracic Society, San Francisco, May: Overview of tumour immunobiology, immunotherapy, and update on recent clinical trials.

#### Invited speaker, panel member, session chair

International Mesothelioma Interest Group (iMig), September, Boston, Massachusetts, USA.

Panel member: Setting the research agenda for mesothelioma (closing session)

Session chair: New directions and future studies; tumour microenvironment workshop; immunology workshop.

## 2011

#### Invited Speaker

World Conference on Lung Cancer (WCLC), July Amsterdam, The Netherlands.

Mesothelioma mini-symposium, "Recent studies in mesothelioma biomarkers and treatment", September, Caen, France.

Lecture, Pulmonary and Thoracic Oncology Department L'Hopital Calmette, "Recent studies in mesothelioma biomarkers and treatment.", CHRU de Lille, September, Lille, France.

Cancer Research Institute 19th Annual International Symposium "Immune Effector Mechanisms in Tumor Immunity", October, New York, NY, USA.

16<sup>th</sup> Congress of the Asian Pacific Society of Respiriology, November, Shanghai, China.

## 2010

#### Invited Speaker

Postgraduate course on occupational lung disease, January, Jakarta, Indonesia.

American Association of Immunology, May, Baltimore, Maryland, USA.

National Cancer Institute, May, Bethesda, Maryland, USA.

Translational Medicine in Occupational Lung Disease, August, PIPKRA, Jakarta, Indonesia.

International Congress of Immunology, August, Kobe, Japan.

International Mesothelioma Interest Group (iMig) 10<sup>th</sup> Annual Scientific Meeting, September, Kyoto, Japan.

## 2009

### International

#### Invited Speaker

13<sup>th</sup> World Conference on Lung Cancer (WCLC), July/August. San Francisco, California USA.

Gordon Research Conference on Antigen Cross-Presentation, June, Lucca (Barga) Italy.

Asian Asbestos Conference, April, Hong Kong.

Keystone Symposium on Tumor Immunology, January, Snowbird Utah, USA.

### National

TSANZ, April, Darwin

## 2008

### International

#### Invited Speaker

American Thoracic Society ASM, May, Postgraduate Course lecturer, Toronto Canada.

UK House of Commons Subcommittee on Asbestos Diseases, May, London UK.

International Mesothelioma Interest Group (iMig) conference, September, Amsterdam, The Netherlands.

European Respiratory Society ASM, October Berlin, Germany.

**National**

Invited Lecture

Presidential Award Lecture, March, TSANZ, Melbourne.

**2007**

Invited participant

Gordon Conference: New Frontiers in Cancer Detection & Diagnosis. January, Ventura Beach, California, USA.

Invited Speaker

Thoracic Surgery, Brigham and Women's Hospital, May Boston, Massachusetts USA.

Pfizer Pharmaceuticals, May New London, Connecticut, USA.

NYU, May, New York, New York, USA.

ATS Meeting Plenary, May San Francisco, California USA.

Invited Lecturer

Biotherapy Symposium, Hangzhou, China. June.

Sekelas Kedokteran, Universitas Indonesia. July.

Invited presentation:

Biomarkers for Malignant Mesothelioma TSANZ 2007 ASM, March, New Zealand.

**National**

Invited Lecture, Asia Pacific Society of Respiratory Conference, Queensland.

**2006**

**International**

Invited Speaker

*Tumour antigen cross-presentation*, INSERM, Institut Gustave Roussy, Villejuif, Paris, France.

*Tumour antigen cross-presentation - using a tumor as its own vaccine*, Ludwig Institute, UCL (Universite Catholique de Louvain) Brussels campus, Belgium.

*Mesothelioma*, Service de Pneumologie, Hopital de Brabois, CHU de Nancy, France.

*Serum biomarkers of lung malignancy*, INSERM, Grenoble, France.

*Lung biomarkers*, Centre for Respiratory Research, Rayne Institute, London.

*New mesothelioma biomarkers and therapies*, Royal Marsden Hospital, London.

*Biomarkers, New immunotherapies and Integrated therapy* - 8th International Conference of the International Mesothelioma Interest Group, Chicago, Illinois USA.

**National**

Invited Speaker

Advanced Trainee Workshop: *A balanced life as a doctor*, TSANZ, Canberra.

*Mesothelioma advances*, Australian Lung Foundation (ALF) Lung Cancer Symposium

*Biomarkers for mesothelioma*, SIG Symposium.

*Mesothelioma and biomarkers; Medical response to the Indian Ocean Tsunami in Aceh*, Royal Melbourne Hospital, Melbourne.

*Tumour antigen cross-presentation - biology and significance; The Indian Ocean Tsunami in Aceh*, Peter McCallum Cancer Centre, Melbourne.

**2005**

Invited Speaker:

Keystone Tumor Immunology Conference, February Colorado, USA.

World Lung Cancer Congress, July, Barcelona, Spain.

International Mesothelioma Congress, December, Antalya, Turkey.

**2004**

**International**

Invited Speaker:

International Mesothelioma Interest Group, Brescia, Italy.

International Congress Immunology, Montreal, Canada.

International Association for the Study of Lung Cancer (IASLC), Zurich.

Global Asbestos Congress, November, Tokyo, Japan.

## 2003

### International

#### Invited Speaker:

Mesothelioma - new approaches, May, World Lung Cancer Conference, Vancouver BC, Canada.

#### Invited Lectures

San Francisco General Hospital, USA.

Berkeley University, Berkeley, California, USA.

University of Chile, Santiago, Chile.

UCLA, Los Angeles, USA.

NIH, Bethesda, MD, USA.

RPMS, Imperial College, London, UK.

University of California San Francisco, California USA.

Sir William Dunn School of Pathology, Oxford University, UK.

John Radcliffe Hospital, Oxford, UK.

Biovex, Oxford, UK.

Corixa Corp, Seattle, Washington, USA.

Eli Lilly Corp, Indianapolis, Indiana, USA.

Pacific Northwest Research Institute, Seattle, Washington, USA.

University of Washington, Seattle, Washington, USA.

University of British Columbia, Vancouver, BC, Canada.

## 2002

### International

#### Invited Speaker

*Mesothelioma genetics and therapy*, May, Heidelberg Mesothelioma Conference, Heidelberg, Germany.

### National

#### Invited speaker

*Biology and Therapy of Mesothelioma* TSANZ March, Cairns.

*Biology and Gene Therapy of Mesothelioma*, June, Dust Diseases Board of NSW. Sydney.

*Tumour antigen cross-presentation*, March, Princess Alexandra Hospital, Brisbane.

## 2001

### National

#### Invited Speaker

*Vaccinia-IL2 use in animal models and human trials*, Australasian Gene Therapy Society Annual Meeting, Sydney.

*Transfection-transgenic analysis of CD40 interactions*, Australasian Society for Immunology, Tumor Immunology Workshop.

## 2000

### International

#### Invited Speaker and Workshop Chairman

*Tolerance and anti tumour immunity*: Keystone Conference on Tumour and Cellular Immunology, January, Santa Fe, New Mexico, USA.

#### Invited Symposium Speaker

*TCR Transgenic cells in lung research*, American Thoracic Society International Conference, May, Toronto, Canada.

### National

#### Invited Chairman

ATS Postgraduate Course on Advanced Techniques in Molecular Biology.

## 1999

### International

#### Invited Speaker

*Advanced Techniques in Molecular Biology and Immunology*, American Thoracic Society International Conference, April, San Diego, California, USA.

**National**

Invited Speaker

*Gene Therapy of Cancer*, Australasian Pharmaceutical Sciences Association Meeting.

**1998**

**International**

Invited Symposium Speaker and Co-Chair

*Gene therapy of mesothelioma immune approaches*, American Thoracic Society International Conference, Chicago, Illinois USA.

Invited Lecture

*Use of TcR transgenics to analyse anti-tumour immune responses*, University of Chicago, Chicago, Ill. USA.

*Use of TcR transgenics to analyse anti-tumour immune responses*, Pittsburgh Cancer Centre, Pittsburgh, Penn. USA.

Invited Lecture

*Use of TcR transgenics to analyse anti-tumour immune responses*, RPMS, Imperial College, London, UK.

**National**

Invited Symposium Speaker

*Gene therapy for lung cancer*, SANZ Annual Scientific Meeting, April, Adelaide.

Invited Speaker

*Autoimmunity and tumour immunology*, John Curtin School of Medical Research, Autoimmunity Workshop, December, Canberra.

*Basic aspects of lung immunology*, 5<sup>th</sup> Asia-Pacific Congress of Respiriology, Sydney.

**1997**

Invited Lecture:

Australasian College of Physical Scientists and Engineers in Medicine, Annual Scientific Meeting, Perth, Australia. "Research in a teaching hospital".

Invited Speaker & Co-Chairman:

International Mesothelioma Interest Group Scientific Meeting, Philadelphia, USA. "Immunological approaches to gene therapy of mesothelioma".

Invited Symposia Speaker & Co-Chairman:

World Lung Cancer Conference, Dublin, Ireland. "Gene therapy of lung malignancies"

**1997**

Invited Speaker:

Australian College of Physical Scientists and Engineers in Medicine, Sir Charles Gairdner Hospital, Western Australia, August, 1997. "The role of medical research in major teaching hospitals".

Invited Speaker:

Australian Tumour Immunology Workshop, Perth, Australia, December, 1998. "Immunotherapy approaches to mesothelioma".

**1996**

**International**

Invited Speaker

*Immune responses in the lung*, Asia Pacific Society of Respiriology, Beijing, China.

*Gene transfer and antisense approaches to cancer*, Biomedical Research Centre, Vancouver, BC, Canada.

**National**

Invited Symposium Speaker

*Gene therapy of cancer*, 10<sup>th</sup> International Biotechnology Symposium, Sydney.

Invited Speaker:

*Gene transfer approaches in cancer*, Australian Tumour Immunology Workshop, December, Daydream Island, Queensland.

**1995**

**International**

Invited Symposium Speaker and Chairman

*Immunology of Mesothelioma; Potential for Gene Therapy of Mesothelioma*, September, International Mesothelioma Conference, Paris, France.

Invited Lecture

*Gene therapy of mesothelioma*, Gene Therapy Inc, September, Gathersburg, Maryland, USA.

*MHC Molecules and Immune Recognition of Tumours*, September, University of Maryland, Maryland, USA.

*Co-stimulation, Immune Recognition and Immune Deviation in Tumour Immunology*, September, Dept of Oncology, Johns Hopkins Medical School, Baltimore, Maryland, USA.

*Immune Deviation, Co-stimulation and Antisense Inhibition in Tumour Immunology*, National Cancer Institute (NIH), September, Frederick, Maryland, USA.

**National**

Invited Symposium Speaker

*Cytokines and the Molecular Biology of Mesothelioma*, Asbestos Medico-Legal Conference, November, Sydney.

Invited Speaker

*B7 transfection and immune anti-tumour responses*, Australian Society for Immunology Annual Scientific Meeting, December, Gold Coast.

**1994**

**International**

Invited Symposium Speaker

*Basic Biology of Mesothelioma*, European Respiratory Society Annual Scientific Meeting, October, Nice, France.

Invited Symposium Speaker

*Early Staging of Mesothelioma and Clinical Symptoms in the Staging of Mesothelioma*, World Congress on Lung Cancer, Colorado Springs, Colorado, USA.

**National**

Invited Symposium Speaker:

*Aetiology and pathogenesis of mesothelioma*, International Meeting on Lung Tumours, European School of Oncology, September, Sydney.

Invited Lecture:

*Lung immunology and molecular biology*, June, University of Sydney.

*The molecular immunology of lung disease*, Thoracic Society of Australia & New Zealand - NSW Branch, June, Sydney.

**1993**

Invited Symposium Lecture

*Immunobiology of pulmonary tumours*, International Congress on the Regulation of Leukocyte Production and Immune Function, Society for Leukocyte Biology and Australian Society for Immunology, December, Sydney.

Invited Plenary Speaker

*Current Concepts in Lung Immunology*, Thoracic Society of Australia and New Zealand, Annual Scientific Meeting, May.

Invited Speaker (breakfast session)

*Pulmonary sarcoidosis*, Thoracic Society of Australia and New Zealand, Annual Scientific Meeting, May.

Invited Symposium Chairman and Speaker

*Novel Gene transfer and cytokine approaches in pulmonary malignancy; Novel approaches to cancer*, Clinical Oncology Society of Australia, Annual Scientific Meeting, November.

**1992**

Invited Lecture:

London Chest Hospital, UK. "Mesothelioma - current concepts."

Invited Lectures:

St. Mary's Hospital, UK "T cells and the human lung" (October 1992) "Immunobiology of asbestos-induced cancer" (October 1992); Granulomatous Lung Disease Seminar (November 1992).

Invited Lecture:

National Cancer Institute, NIH, USA “Antisense oligonucleotide strategies in evaluating autocrine growth factors”.

Invited Lecture:

The Blood Center, Milwaukee, USA. “Lung T cell clones”.

Invited Lectures:

Departments of Immunopathology and Respiratory Medicine, Massachusetts General Hospital, Boston, USA. “Malignant mesothelioma” and “Human lung T cell clones and sarcoidosis”.

Invited Lecture:

Mt. Sinai Medical Center, New York, USA. “Current concepts of mesothelioma”.

Invited Lecture:

New York University Medical Center, Bellevue Hospital, New York, USA. “Mesothelioma”

Invited Lecture:

St. Bartholomew’s Hospital, London, United Kingdom. “Current concepts of mesothelioma”.

Invited Lectures:

National Heart and Lung Institute, Brompton Hospital, London, United Kingdom. “New approaches to the therapy of mesothelioma” and “The immunobiology of asbestos-induced cancer”.

Invited Lecture:

Whittington Hospital, London, United Kingdom. “Biology and therapy of solid human tumours”.

**1992**

Invited Symposium Chairman:

Thoracic Society of Australia and New Zealand, Annual Scientific Meeting, April 1992. “Airway Inflammation”

**1991**

Invited Speaker:

International Conference on Mesothelioma, Paris, 1991. “Scientific basis of the immunotherapy of malignant mesothelioma”.

Symposium Chairman:

International Conference on Mesothelioma, Paris, 1991. “Biology and Mesothelioma”

Invited Speaker:

World Lung Cancer Conference, IUSLC, 1991. “Malignant mesothelioma: Development of new therapeutic strategies”.

Invited Chairman:

World Lung Cancer Conference, IUSLC, 1991. Mesothelioma symposium.

**1991**

Invited Symposium Speaker:

Thoracic Society of Australia and New Zealand, Advanced Course, November 1991. ‘Molecular Biology’

Invited Symposium Chairman:

Australian Society for Immunology, Annual Scientific Meeting, December 1991. ‘Tumour Immunology’

Invited Workshop Chairman:

Australian Society for Immunology, Annual Scientific Meeting, December 1991. ‘Tumour Immunology’

**1990**

Invited Lecture:

Symposium on Health Effects of Grain and Other Organic Dusts, Perth, March 1990. “Cells, cytokines and organic dust exposure”.

Invited Lecture:

International Conference on the Immunotherapy of Melanoma and other Cancers, Newcastle, September 1990. “Interferon and interleukin-2/LAK cell therapy in mesothelioma”.

**1990**

Invited Chairmanship:

Thoracic Society of Australia Young Investigator Award Session, April 1990.

Invited Lecture:

Recent Advances in Lung Cancer: Clinical Oncology Society of Australia/Thoracic Society of Australia Joint Symposium, April 1990. “Mesothelioma - from laboratory to bedside”.

Invited Lecture:

Royal Prince Alfred Hospital, Sydney, New South Wales, August 1990. "Current concepts of mesothelioma".

Invited Lecture:

National Scientific Meeting, Australian Institute of Medical Laboratory Scientists, September 1990, Perth. "Cytokines".

**1989**

Invited Lecture:

Brompton Hospital, London 1989. "Malignant mesothelioma - oncogenes, growth regulation and immunological features".

Invited Lecture:

Hopital Bichat, Paris, 1989. "Immunotherapy of malignant mesothelioma".

**1989**

Invited Lecture:

Royal Adelaide Hospital, December 1989. "Pulmonary Sarcoidosis: current concepts".

**1988**

Invited Lecture:

The Australian Society for Medical Research: Symposium on Lung Cancer, 1988. "An Overview of Pulmonary Tumors: Immunological Aspects".

Invited Lecture:

Australian Cytokine Research Association, Sydney, 1988. "Interleukin-2".

Invited Lecture:

Society of Hospital Pharmacists, Annual Meeting, 1988. "The Immune System" and "Drugs and the Immune System".

**1987**

Invited Lecture:

National Cancer Institute, Washington, DC, May 1987. "NK cells in the human lung".

Invited Speaker:

Cardiothoracic Unit, Brompton Hospital, London, England. May, 1987. "Mechanism Underlying Epithelial Cell Damage in Human Asthma".

**1987**

Invited Participant:

National Working Party on Immunotherapy and Cancer, 1987.

Invited Lecture:

International Interest Group Biennial Conference, Perth Dec 2002. "Mesothelin as a novel serum marker for mesothelioma".

Invited Lecture:

Advanced Technologies in Cancer - from Gene Chips to Gene Therapy Perth Dec 2002. "The scientific basis for immunogene therapy".

Invited Lecture:

Thoracic Society of Australia, Annual Scientific Meeting, June 1987. "The Cell Biology of Human Lung Cancer".

Invited Chairmanship:

Thoracic Society of Australia, Annual Scientific Meeting, June 1987. "Lung Cell Biology Poster Symposium".

Invited Chairmanship:

Thoracic Society of Australia Cell Biology Symposium, 1987. "Current Concepts of Lung Cell Biology".

**1986**

Invited Speaker:

Cardiothoracic Unit, Brompton Hospital, London, England, May, 1986. "BAL studies in Interstitial Lung Diseases".

Invited Presentation:

Aspen Lung Conference, Aspen, Colorado, June 1986. "Interleukin-2, natural killer cells and lung cancer."

**1986**

Session Co-Chairman:

Thoracic Society of Australia, Annual Scientific Meeting, June, 1986. "Bronchoalveolar Lavage".

Chairman:

Thoracic Society of Australia, Annual Scientific Meeting, Cell Biology Symposium, June, 1986.

Invited Lecture:

Australian Medical Laboratory Technology Society, Annual Scientific Meeting, Oct, 1986. "Interleukin-2".

**1985**

Symposium Co-Chairman:

World Congress on Diseases of the Chest, August, 1985. "Bronchoalveolar Lavage in Interstitial Lung Disease."

Invited Speaker:

World Congress on Diseases of the Chest, August, 1985. "Use of bronchoalveolar lavage in evaluating asbestosis and pulmonary connective tissue diseases"

Invited Speaker:

World Congress on Diseases of the Chest, August, 1985. Cell Biology Symposium "Lymphocyte-Macrophage Interactions".

**1985**

Invited Lecture:

Walter and Eliza Hall Institute of Medical Research, Melbourne, July 1985. "Immunological processes in the normal and diseased human lung".

Invited Lecture:

John Curtin School of Medical Research, Canberra, July 1985. "Methods of evaluating pulmonary inflammation, anti-tumour activity and protease activity in the normal and diseased human lung".

Invited Speaker:

National Symposium on Gamma Interferon, Clinical Oncology Society of Australia Annual Scientific Meeting, November, 1985. "Gamma Interferon - Biological Role and Potential Clinical Uses."

Invited Speaker:

National Bronchoscopy Symposium, Thoracic Society of Australia, November, 1985. "Clinical Experience with Bronchoalveolar Lavage".

**1984**

Invited Lecture:

Tufts New England Medical Centre, Boston, USA. January 1984. "Pulmonary NK cells and their regulation by interleukin-2 and gamma-interferon".

**1984**

Invited Speaker:

Royal College of Pathologists of Australasia Annual Scientific Meeting, October 1984. "New Methods of Evaluating Patients with Interstitial Lung Disease".

Symposium Co-Chairman:

Australian Society for Immunology, Annual Meeting, December 1984. "Lymphokines".



## 8. RESEARCH GRANTS AWARDED

Year Awarded	Funding Body	Title	Investigators	Amount
2018-2020	NHMRC	Project grant 11144209: The relationship between cancer surgery, lymph nodes, T cells and immunotherapy	<b>BWS Robinson, C Saunders, M Brown, V Fear, J Waithman, J Chee</b>	\$960,585
2018-2020	NHMRC	Project grant 1146909: The impact of therapy on T-cell recognition of mutated tumour neo-antigens	<b>BWS Robinson, AK Nowak, M Millward, J Creaney, R Holt, M Watson</b>	1,111,128
2017-2020	NHMRC	Compartmental analysis of the magnitude and range of tumour neoantigen specific CD8 T cell responses in patients with lung malignancies	<b>BWS Robinson, YCG Lee, J Creaney, R Lake, R Holt, A Nowak, M Watson, J Pearson, J Chee</b>	\$851,403
2017	Cancer Council WA	The impact of therapy on T-cell recognition of mutated tumour neo-antigens	<b>BWS Robinson, A Nowak, M Millward, J Creaney, R Lake, R Holt, M Watson, N Waddell, J Chee</b>	\$100,000
2017	Cancer Council WA	The effect of FGF9 on anti-tumour immunity in mesothelioma	S Lansley, YCG Lee, J Creaney, <b>BWS Robinson</b>	\$81,581
2016-2020	NHMRC	Practitioner Fellowship	<b>BWS Robinson</b>	\$561,362
2016-2020	WA Dept of Health	Provision of research services related to treatments for asbestos induced diseases	<b>BWS Robinson, R Lake, A Nowak, J Creaney, S Fisher</b>	\$1,000,000
2016-2020	NHMRC	Centre for Research Excellence: National Centre for Asbestos Related Diseases	<b>BWS Robinson, J Creaney, R Lake, A Nowak, AW Musk, WJ Lesterhuis, YCG Lee, R Francis, R Holt, N Waddell</b>	\$2,500,000
2016-2018	NHMRC	Reactivities of CD8 T cells to mutated neoantigens in lung malignancies.	<b>BWS Robinson, J Creaney, R Lake, WJ Lesterhuis, M Watson</b>	\$661,976
2016	Cancer Council WA	Tracking the T cell repertoire at the tumour site in mesothelioma and lung cancer	A McDonnell, A Nowak, R Lake, <b>BWS Robinson, J Creaney, YCG Lee, M Linden, A Cook</b>	\$99,752
2015-2017	NHMRC	Project grant 1089404: Characterising the mutations, signatures, potential new therapeutic targets and biomarkers in malignant mesothelioma using whole genome analysis.	N Waddell, J Creaney, <b>BWS Robinson, J Pearson, &amp; S Grimmond</b>	\$1,188,475
2014-2016	NHMRC	Improving treatment outcomes for malignant mesothelioma patients using biomarkers	J. Creaney, S. Skates, <b>B. Robinson, A. Nowak, AW. Musk</b>	\$769,086

2014	WA Dept of Health	Preclinical and clinical trials	<b>NCARD</b>	\$200,000
2014	WA Dept of Health	Enabling grant	<b>NCARD</b>	\$123,818
2013-2017	Insurance Commission of WA	Improving the diagnosis and treatment of early mesothelioma	<b>BWS Robinson, R Lake, J Creaney</b>	\$1,958,335
2013-2016	Ross Divett Foundation	Ross Divett Scholarship funds	NCARD	\$400,000
2013	Housing Industry Association Charitable Foundation	Alcock Brown-Neaves (\$325,000); Housing Industry Association Charitable Foundation (\$50,000); WA Charity Direct (\$25,000)	National Centre for Asbestos Related Diseases, Director: BWS Robinson	\$400,000
2013	NHMRC	Equipment Grant: Chemidoc	<b>BWS Robinson, J Creaney, A Nowak, R Lake</b>	\$42,500
2013-2015	NHMRC	Project grant 1050938: Novel surgery-chemotherapy-immunotherapy approaches for lung malignancies	<b>BWS Robinson, M Millward, RA Lake, J Alvarez</b>	\$639,873
2013	US Depart of Defense	Peer Review Cancer Research Program Discovery Award:Targetting immunological "restrainers"...	BW Robinson	\$269,850
2013	WA Dept of Health	Preclinical & Clinical Trials Enabling Grant	NCARD	\$51,666
2012-2013	Dust Diseases Board of NSW	Releasing the brakes on anti-tumour immune responses using chemo-immunotherapy in the treatment of mesothelioma	BWS Robinson	\$160,000
2012-2014	NHMRC	Project grant 1029589: Cross presentation and tumour immunology	BWS Robinson, RA Lake, A Nowak	\$429,925
2012	WA Dept of Health	Preclinical & Clinical Trials Enabling Grant	NCARD	\$103,332
2012-2013	Sir Charles Gairdner Hospital	An investigation of the metabolic acquisition of pemetrexed resistance in malignant mesothelioma	J.Creaney, A. Nowak, <b>B. Robinson</b>	\$49,873
2011	WA Dept of Health	Preclinical & Clinical Trials Enabling Grant		\$103,332
2011-2012	Cancer Council of WA	Determining the phenotype & function of cells in the tumour environment that suppress CD8 T cell function and proliferate during anti-PD-L1 tumour therapy	<b>B Robinson, A Cleaver, RA Lake, A Marzo</b>	\$165,000
2010-2012	NHMRC	Project grant 634377: Is MUC1 a viable therapeutic target for patients with the asbestos-induced tumour malignant mesothelioma?	J Creaney, A Segal, <b>B Robinson, A Nowak</b>	\$448,500
2010-2014	NHMRC	Centre for Research Excellence: National Centre for Asbestos Related	<b>B Robinson; J Creaney; A Nowak; R Lake; A Musk; B</b>	\$4,500,000

		Diseases	Fazekas de St Groth; L Palmer; R Simpson; S Skates; D Watkins	
2010-2015	University of Western Australia	Research matching funds for CRE	NCARD	\$250,000
2009-2011	NHMRC	Project grant 572669: Combining surgery and immunotherapy to treat cancer of lung	<b>BW Robinson, J Alvarez, A Currie, RA Lake</b>	\$496,250
2009-2011	NHMRC	Project grant 572593: Optimising regulatory T cell depletion in combination with chemotherapy...	AK Nowak, RA Lake, MJ Millward, R van der Most, <b>BW Robinson</b>	\$254,250
2008-2010	NHMRC	Project grant 513804: NK cells as the missing link between anti-cancer chemotherapy and DC8 T cell response	RA Lake, R van der Most, AK Nowak, <b>BW Robinson</b>	\$468,750
2008-2010	NHMRC	Diagnostic markers for malignant mesothelioma and other respiratory diseases	<b>BWS Robinson, J Creaney, AW Musk, S Skates</b>	\$448,500
2007-2011	NHMRC	Strategic Award 46913 National Asbestos Research grants to form a National Centre for Research in Asbestos Related Diseases (NRCARD)	<b>BWS Robinson, PJ Thompson, AW Musk, RA Lake, S Mutsaers, AK Nowak</b>	\$2,000,000
2007-2009	NHMRC	NRCARD grant 458520 The Genetic Understanding of Asbestos-Related Disorders (GUARD)	L Palmer, AW Musk, M Garlepp, N de Klerk, A Reid, BWS Robinson	\$543,600
2007-2009	NHMRC	NRCARD grant 458532 Sensitive serum markers for improved diagnosis, monitoring and screening for early detection of mesothelioma	J Creaney J, BWS Robinson, AW Musk, SJ Skates	\$389,775
2007-2009	NHMRC	NRCARD grant 458533: Integrating conventional mesothelioma therapies with immuno- and gene therapies	<b>B Robinson, P Reynolds, A Currie, R van der Most, RA Lake, AK Nowak</b>	\$287 965
2006	NIH Early Detection Research Network (ERDN)	American-Australian biomarker discovery consortium	H Pass (NYU), B Robinson	\$450,000
2005-2007	NHMRC	Grant 350466: Molecular characterisation and diagnosis of malignant mesothelioma	A Holloway, B Robinson, R Lake	\$417,000
2005-2007	NHMRC	Project grant 353632: Tumour antigen cross-presentation: efficiency, biology and role of inhibitory B7 homologue molecules	BWS Robinson, R Lake, D Nelson	\$462,750
2005-2007	NHMRC	Project grant 353631: Serum mesothelin-related protein as an early marker of mesothelioma	BWS Robinson, AW Musk, R Lake, J Creaney	\$350,250

2004-2009	Australian Tissue Biospecimen Network	Enabling grant 310670	L Devereux, D Catchpoole, A de Fazio, A Holloway, R Lake, B Robinson, C Schmidt, H Thorne, N Zeps	\$1,750,000
2004	NH&MRC	Year 2 of 2003-2005 SMF grant 254665): SMF in mesothelioma patients		\$102,500
2004-2006	NH&MRC	Grant 350466: Molecular Analysis of Malignant Mesothelioma	<b>BWS Robinson, A Holloway, RA Lake</b>	\$416,900
2004-2006	NH&MRC	Grant 353632: Tumour antigen cross-presentation: efficiency, biology and role of inhibitory B7 homologue molecules	<b>BWS Robinson, RA Lake, D Nelson</b>	\$462,750
2004-2006	NH&MRC	Grant 353651: Serum mesothelin-related protein as an early marker of mesothelioma	BWS Robinson, AW Musk, RA Lake, J Creaney	\$350,250
2003-2005	NH&MRC	Grant 254665: Clinical utility of a novel serum marker, serum mesothelin family protein (SMF) in mesothelioma patients	BWS Robinson, R Lake, J Creaney, AW Musk	307,500
2003-2006	Health Dept of WA	Clinical Trials		\$386,139
2002-2006	WA Insurance Commission	Markers of mesothelioma		\$1,194,400
2001-2003	NH&MRC	Grant 211999: Evaluation of immune response to multiple tumour antigens during tumour growth	<b>BWS Robinson, D Nelson</b>	\$450,000
2000-2002	Dust Diseases Board of NSW			\$274,000
2000-2002	NH&MRC	Grant 9936584: Persistent intratumoral cytokines and antitumor immunity	<b>BWS Robinson, RA Lake, B Scott</b>	\$222,600
1999-2001	NH&MRC	Grant 993721: Regulation of immune responses by cognate oligomerisation of MHC class II with the T cell	<b>BWS Robinson, J Hayball, RA Lake</b>	\$228,700
1997-1999	Australian Lung Foundation	Gene therapy of mesothelioma: pre-clinical and clinical studies	<b>BWS Robinson, B Scott, RA Lake</b>	\$117,682
1997-1998	MEDWA	Lung cancer immunology		\$100,000
1997	NH&MRC	Equipment Grant	<b>BWS Robinson, G Shellam, G Stewart, P Thompson</b>	\$105,000
1997	Lotteries Commission	Fluorescence activated cell sorter	<b>BWS Robinson, G Shellam, G Stewart, P Thompson</b>	\$191,000
1997-1999	NH&MRC	Blockade of tumour	<b>BWS Robinson, RA</b>	\$186,621

		transforming growth factor-beta to boost anti-tumour immunity	Lake	
1997-1999	NH&MRC	Tumour antigen presentation in a transfection-transgenic tumour model	<b>BWS Robinson, B Scott</b>	\$125,774
1996	Cancer Foundation of Western Australia	An investigation of the induction of lymphocyte apoptosis as a mechanism by which tumours subvert the immune response	<b>BWS Robinson, B Scott</b>	\$24,000
1996-1999	NH&MRC	A novel transgenic-transfection model to evaluate tumour-lymphocyte interactions	BWS Robinson, B Scott, M Garlepp	\$151,336
1995	MEDWA	Antisense and mesothelioma		\$29,000
1994-1998	SCGH Foundation	Molecular biology fellowship		\$310,000
1994-1998	SCGH Foundation	Cellular immunology fellowship		\$310,000
1994-1996	NH&MRC	Immunology, anergy and malignant mesothelioma	<b>BWS Robinson, H Bielefeldt-Ohmann, D Fitzpatrick</b>	\$268,017
1994-1996	NH&MRC	Antisense strategies in malignant mesothelioma	BWS Robinson, D Fitzpatrick, H Bielefeldt-Ohmann	\$152,487
1994-1996	SGIC/SCGH	Local cytokines and cancer	<b>BWS Robinson</b>	\$342,000
1994	MEDWA	Delivery of anti-sense molecules by liposomes		\$59,572
1994	SCGH Foundation	Clinical trials fellowship	<b>BWS Robinson, AW Musk</b>	\$240,000
1994	Asthma Foundation	IL-12 in asthma airways	<b>BWS Robinson, J Upham</b>	\$36,000
1993	SCGH/SGIC	Mesothelioma mutations	<b>BWS Robinson, AW Musk</b>	\$59,000
1993	UWA Faculty of Medicine	Enhancement of immune responses to malignant mesothelioma by cytokine gene transfer	<b>BWS Robinson, C Leong, M Garlepp</b>	\$8,000
1993	UWA Faculty of Medicine	The role of transforming growth factor- $\beta$ in mesothelioma tumour growth <i>in vitro</i> and <i>in vivo</i>	<b>BWS Robinson, D Fitzpatrick</b>	\$6,500
1993	MEDWA	Delivery of anti-cancer agents to mesothelioma tumours <i>in vivo</i>	<b>BWS Robinson, D Fitzpatrick</b>	\$48,800
1993-1995	MEDWA	Transfection of cytokine genes as a means of inducing immunity to malignant mesothelioma	<b>BWS Robinson, C Leong, M Garlepp</b>	\$135,000
1993	Cancer Foundation	Control of mesothelioma growth <i>in vitro</i> and <i>in vivo</i> by antisense strategies	BWS Robinson, D Fitzpatrick and M Garlepp	\$15,000
1992	Asthma Foundation	T-cells and asthma	<b>BWS Robinson, J Upham</b>	\$24,000
1992	Cancer Foundation	MHC gene transfection	BWS Robinson, M	\$37,000

			Garlepp	
1991	SCGH Research Foundation (SGIC grant)	Mesothelioma	BWS Robinson, L Manning, D Whitaker, M Garlepp, AW Musk	\$41,000
1991	Health Dept Grant (WA Govt)	Cytokine clinical trials		\$134,000
1991-1996	James Hardie Industries	Molecular biology scientific research fellowship		\$400,242
1991	SCGH Research Foundation (SGIC grant)	Pathogenesis of asbestosis	BWS Robinson, AW Musk, R Bowman	\$48,000
1991-1992	Hoffman La Roche	Interferon + Doxorubicin in mesothelioma		\$80,000
1991	Cancer Foundation of WA	MHC gene transfection	BWS Robinson, M Garlepp, L Manning	\$27,882
1991	Cancer Foundation of WA	Mesothelioma immunity	BWS Robinson, L Manning	\$40,000
1991-1993	Worksafe Australia	Workplace chemicals and asthma	BWS Robinson, A James, AW Musk	\$150,000
1991	UWA Faculty of Medicine	Mesothelioma monoclonals	BWS Robinson, L Manning	\$9,000
1990-1993	NH&MRC	Project Grant: Lung T cells	BWS Robinson, M Garlepp, AW Musk, P Holt	\$328,000
1990	Asthma Foundation (WA)	Lung T cells in asthma		\$25,000
1990	Hoffman La Roche	Alpha interferon and mesothelioma		\$40,000
1990	Cancer Foundation	Mesothelioma monoclonals	BWS Robinson, L Manning, D Whittaker	\$14,000
1989	Workers Compensation Commission/Health Dept	Mesothelioma therapy		\$134,000
1989	Hoffman La Roche	Alpha interferon in mesothelioma		\$40,000
1989	Telethon Foundation	Asthma		\$15,000
1989	CF Association	Epithelial damage		\$38,247
1989	Cancer Foundation	Cytokines and DFMO	BSW Robinson, R Minchin	\$25,000
1988	Telethon Foundation	Asthma		\$24,000
1988	CF Association	Epithelial damage		\$19,000
1987-1988	SCGH Philanthropic Grant	Mesothelioma/IL-2 and LAK therapy	BWS Robinson, AW Musk	\$450,000
1987	CF Association	Cystic fibrosis	BWS Robinson, P Holt	\$10,500
1987-1989	NH&MRC	Project Grant: Gamma interferon	BWS Robinson, AW Musk	\$223,163
1986	NH&MRC	Fellowship: Bronchoalveolar lavage		\$50,173
1986	SCGH	Project Grant: Sarcoidosis	BWS Robinson, AW Musk	\$22,224
1986	Asthma Foundation	Epithelial cell damage		\$24,000
1986	Australian Kidney Foundation	Uraemia and immune defences		\$9,500

1986	UWA Faculty of Medicine	Tumour immunology		\$4,000
1986-1998	Worksafe Australia	Occupational asthma and airway damage	BW Robinson, AW Musk, G Ryan	\$99,702
1986	Telethon Trust	Asthma		\$22,360
1986	Telethon Trust	Cystic fibrosis	BWS Robinson, P Holt	\$22,000
1985	SCGH Project Grant	Sarcoidosis	BWS Robinson, AW Musk	\$26,500
1985	Asthma Foundation	Epithelial cell damage		\$6,000
1985	UWA Faculty of Medicine	Tumour immunology		\$4,000
1982-1986	NH&MRC	Fellowship: Mechanisms of alveolar damage		\$104,755
1981	UWA Saw Fellowship	Lung immunology		\$17,500
1981	RACP Fellowship	Lung Immunology		\$4,500

## 9 RESEARCH GROUP

### 9.1 Current Tumour Immunology Group

#### Leadership group

Professor Bruce Robinson  
 Professor Jenette Creaney  
 Professor Richard Lake  
 Professor Anna Nowak  
 Dr Joost Lesterhuis  
 Dr Jon Chee  
 Dr Alistair Cook  
 Dr Ian Dick  
 Dr Vanessa Fear  
 Dr Scott Fisher  
 Dr Joost Lesterhuis  
 Dr Alison McDonnell

#### 9.2 Doctoral/Other Students (past/present)

Dr Linda Ye, Medical Research Fellow (2017 - current)  
 (co-supervised with Prof Jenette Creaney)  
 Dr Antonius Steven, Respiratory Fellow (2015 - 2016)  
 (co-supervised with Prof Jenette Creaney)  
 Mr Shaokang Ma, Honours student (2014);  
 PhD student (2015 - current; co-supervised with Prof Jenette Creaney)  
 Ms Sophie Sneddon, PhD student (2014 -2017)  
 (co-supervised with Prof Jenette Creaney)  
 Dr Su Lyn Leong, Medical Research Fellow (2012-2013)  
 Dr Chidozie Anyaegbu, PhD student (2010-2016 )  
 (co-supervised with Dr Scott Fisher)  
 Dr Henry Steer, MD student (2009-2011)  
 \*Ms Alison Smith, PhD student (2005-2009)  
 Mr Steve Broomfield, PhD student (2000-2009)  
 Ms Amanda Sherwood, PhD student (2002-2006)  
 (co-supervised with Dr R Lake, D Nelson)  
 \*Dr Matt Brown, PhD student (2005-2009)  
 Ms E. Brooks, BSc (Hons) student (2005)

Mr Paul Chia, MBBS- Vacation scholarship student (2004-2005)  
 (co- supervised with Dr R Lake)  
 Ms Chris Bundell, PhD student (2001-2005)  
 (co-supervised with Dr D Nelson)  
 Ms Connie Jackaman, PhD student (2001-2005)  
 (co-supervised with Dr D Nelson, Jane Allan)  
 Dr Alex Powell, Medical Research fellow (2003-2004)  
 Dr M Murphy, Medical Research fellow (2003)  
 \*Dr Anna Nowak (FRACP), PhD student (1999 -2002)  
 (co-supervised with Dr R Lake)  
 Dr J Chan (FRACP), PhD student (1996 -2001)  
 (co-supervised with Dr R Lake)  
 Mr. Ben Talbot, MBBS-BMedSci student (1999-2000)  
 (co- supervised with Dr R Lake)  
 Dr Sutapa Mukherjee (FRACP), PhD student (1996 -2000)  
 (co-supervised with Dr B Scott & Dr D Nelson)  
 Dr B McLaren (FRACP), MD student (1997 -1999)  
 (co-supervised with Dr R Lake)  
 Ms Amanda Marzo, PhD student (1996 -1999)  
 (co-supervised with Dr B Scott & Dr R Lake)  
 \*Ms I Caminschi, PhD student (1994 -1997)  
 (co-supervised with Dr B Scott & Dr M Garlepp)  
 Dr A Davidson, MD student (1994 -1995)  
 Mr A Jarnicki, BSc (Hons) student (1993-1994)  
 (co-supervised with Dr H Bielefeldt-Ohmann)  
 Mr T Venaille, PhD student (1992-1994)  
 (co-supervised with Prof P Holt)  
 Mr D Peroni, MSc student (1992-1994)  
 (co-supervised with Dr M Garlepp)  
 \*Mr C Leong, PhD student (1992-1994)  
 (co-supervised with Dr M Garlepp)  
 \*Dr N Mavaddat, PhD student (1992-1994)  
 (co-supervised with Dr M Garlepp)  
 \*Dr J Upham, PhD student (1991-1994)  
 (co-supervised with Prof P Holt)  
 Ms J Staton, BSc (Hons) student (1993)  
 (co-supervised with Dr H Bielefeldt-Ohmann)  
 Ms J Dench, BSc (Hons) student (1992)  
 (co-supervised with Dr H Bielefeldt-Ohmann)  
 Dr T Christmas, MD student (1990-1991)  
 \*Dr R Bowman, MD student (1978-1990)  
 Mr R Schultz, medical student vacation scholarship (1988)  
 Ms M John, medical student vacation scholarship (1987)  
 Mr J Flexman, medical student vacation scholarship (1986 & 1987)  
 Mr R Blum, medical student vacation scholarship (1986 & 1987)  
 Ms D Urwin, Honours student  
 (co-supervised with Dr R Lake)  
 Mr S Fisher, Honours student  
 (co-supervised with Dr D Nelson)  
 Ms B. Koloska (PhD student) [deceased]

\* received Young Investigator Awards or other similar awards during these studies.

NB. Numerous medical graduates have also undertaken research work in the lab but not to complete PhD or Masters etc. and several have also won young investigator or similar awards from professional societies.

## 9. TEACHING

### 9.1 Experience



Lectures and seminars to medical students in the 3rd, 4th, 5th and 6th years of their course (respiratory diseases, occupational medicine, molecular immunology) plus clinical teaching plus lectures/tutorials to dental medical students, nursing staff, paramedical staff and medical laboratory technologists. Postgraduate tutorials and clinical teaching.

### **9.2 Teaching initiatives**

Initiated the following components to the medical school curriculum:

1. Course in 'Communication skills in medicine'
2. Teaching Weekend for final year medical students
3. Course in Medical Research for medical students
4. Seminars on medical education for teachers of clinical medicine

### **9.3 Teaching Committees**

1. UDM Academic Staff
2. UDM Local (QEII/MC) Academic Staff
3. Division of Dentistry and Medicine Equipment Allocation Committee
4. Division B Medical Science Working Party
5. Department of General Medicine
6. Department of Respiratory Medicine
7. Teaching and Examinations Committee (1994)
8. RACP Paper C Committee (1991-93)
9. International Conference Committee, American Thoracic Society
10. Cell Biology and Immunology Special Interest Group, TSANZ (Convenor)

### **9.4 Department of Medicine Special Responsibilities**

1. Medicine IV course manager, Sir Charles Gardiner Hospital
2. Medicine IV written examination paper
3. Medicine VI Teaching Weekend (1990-present)
4. Communication Skills Course (Medicine IV, V, VI) (1990-present)
5. Lectures in Medicine III, IV, V, VI (1985-present)
6. Lectures to Dental Medical students (1990-1998)
7. Introductory Course (1988-92)
8. Medical Research Seminars for Medicine VI (1991)
9. Environmental and Occupational Health Seminar for Medicine VI (1990-91)

### **Current:**

1. Teaching medical students clinical skills on the Introductory Course
2. Medicine VI Teaching Weekend - Chairman and organiser
3. Communication Skills Course (Medicine IV) - organiser and presenter
4. Lectures in Medicine (lung diseases, TB etc)
5. Medicine IV course co-ordinator, SCGH site
6. Academic mentor sessions to med IV and med VI students
7. CPC speaker
8. Writer of exam questions for written exams
9. Clinical examiner, Medicine IV, V and VI
10. Medical research for clinicians lecture, med IV